Vaccines and Global Health: The Week in Review
09 July 2022 :: Issue 664
Center for Vaccine Ethics & Policy (CVEP)

This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 23,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click to move among sections]
:: Coronavirus [COVID-19] - WHO
:: Organization Announcements
:: Journal Watch
Milestones, Perspectives

......
......

Monkeypox

Multi-country outbreak of monkeypox, External situation report #1 - 6 July 2022
Edition 1 6 July 2022 | Emergency Situational Updates
PDF: https://cdn.who.int/media/docs/default-source/2021-dha-docs/20220706_monkeypox_external_sitrep_final.pdf?sfvrsn=1b580b3d_4&download=true

Highlights
:: Updates on the multi-country outbreak of monkeypox has transitioned from the Disease Outbreak News to a biweekly situation report. The situation report will provide details such as the latest epidemiology, new guidance documents and updates on WHO advice. For information not included in this report, please see the Disease Outbreak News published on 27 June 2022.
:: WHO published a guidance document to provide public health advice for gatherings during the current monkeypox outbreak on 28 June. The advice was developed for host governments, public health authorities, national or international organizers, and professional staff involved in the planning and delivery of gatherings, including people organizing smaller gatherings or attending gatherings of any type and size.
:: The outbreak continues to primarily affect men who have sex with men who have reported recent sex with one or multiple male partners, suggesting no signal of sustained transmission beyond these networks for now.

Epidemiological Update
From 1 January to 4 July 2022, 6027 laboratory confirmed cases of monkeypox and three deaths have been reported to WHO from 59 countries/territories/areas in five WHO Regions (African Region, Region of the Americas, Eastern Mediterranean Region, European Region, Western Pacific Region) (Table 1). Since the previous Disease Outbreak News was published on 27 June 2022, 2614 new cases, (77% increase) and two new deaths have been reported; nine new countries/territories/areas have reported cases. Ten countries have not reported new cases for over 21 days, the maximum duration of the incubation period of the disease. This is the first time that local transmission of monkeypox has been reported in newly-affected countries without epidemiological links to countries that have previously reported monkeypox in West or Central Africa...

......
......

Featured Journal Content

Vaccine
Volume 40, Issue 28  Pages 3813-3918 (21 June 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/28
Research article  Open access
Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis
Mark M. Janko, Jonah Joffe, Danielle Michael, Lauren Earl, ... Marcia R. Weaver
Pages 3903-3917
Abstract
Background
Rotavirus caused an estimated 151,714 deaths from diarrhea among children under 5 in 2019. To reduce mortality, countries are considering adding rotavirus vaccination to their routine immunization program. Cost-effectiveness analyses (CEAs) to inform these decisions are not available in every setting, and where they are, results are sensitive to modeling assumptions, especially about vaccine efficacy. We used advances in meta-regression methods and estimates of vaccine efficacy by location to estimate incremental cost-effectiveness ratios (ICERs) for rotavirus vaccination in 195 countries.
Methods
Beginning with Tufts University CEA and Global Health CEA registries we used 515 ICERs from 68 articles published through 2017, extracted 938 additional one-way sensitivity analyses, and excluded 33 ICERs for a sample of 1,418. We used a five-stage, mixed-effects, Bayesian metaregression framework to predict ICERs, and logistic regression model to predict the probability that the vaccine was cost-saving. For both models, covariates were vaccine characteristics including efficacy, study methods, and country-specific rotavirus disability-adjusted life-years (DALYs) and gross domestic product (GDP) per capita. All results are reported in 2017 United States dollars.
Results
Vaccine efficacy, vaccine cost, GDP per capita and rotavirus DALYs were important drivers of variability in ICERs. Globally, the median ICER was $2,289 (95% uncertainty interval (UI): $147–$38,993) and ranged from $85 per DALY averted (95% UI: $13–$302) in Central African Republic to $70,599 per DALY averted (95% UI: $11,030–$263,858) in the United States. Among countries eligible for support from Gavi, The Vaccine Alliance, the mean ICER was $255 per DALY averted (95% UI: $39–$918), and among countries eligible for the PAHO revolving fund, the mean ICER was $2,464 per DALY averted (95% UI: $382–$3,118).
Conclusion
Our findings incorporate recent evidence that vaccine efficacy differs across locations, and support expansion of rotavirus vaccination programs, particularly in countries eligible for support from Gavi, The Vaccine Alliance.

COVID Perspectives

TRIPS Council welcomes MC12 TRIPS waiver decision, discusses possible extension
WTO - 6 July 2022
At a meeting of the Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) on 6 July, WTO members welcomed the adoption of the TRIPS waiver decision on COVID-19 vaccines at the 12th Ministerial Conference (MC12) and began discussions on a possible extension to cover the production and supply of COVID-19 diagnostics and therapeutics. Trade officials also exchanged views on how to promote IP licensing to benefit small businesses, inventors and other individuals.

Discussion on the extension of COVID-19 IP waiver
At MC12, trade ministers adopted the Ministerial Decision on the TRIPS Agreement, which gives members greater scope to take direct action to diversify production of COVID-19 vaccines and to override the exclusive effect of patents through a targeted waiver over the next five years. It addresses specific problems identified during the pandemic and aims to help diversify vaccine production capacity. It also contains a commitment that no later than six months from the date of the decision (17 June), members will decide on its possible extension to cover the production and supply of COVID-19 diagnostics and therapeutics.

Many members took the floor to welcome the successful outcome at MC12, saying it proved that WTO members can put aside differences and work together to respond to the most urgent health challenges. A group of developing members who support an extension of the waiver to cover COVID-19 diagnostics and therapeutics circulated a proposal at the meeting including an indicative timeline for the TRIPS Council’s next steps in this regard.

These members argued that the waiver on COVID-19 vaccines falls short of their expectation and is not enough to help developing countries comprehensively address current and future health challenges. Equitable access to therapeutics and diagnostics, as pointed out by the World Health Organization (WHO), is critical in helping detect new cases and new variants. They said this waiver extension needs to be discussed with a sense of urgency given the fact that many least developed countries (LDCs) lack access to life-saving drugs and testing therapeutics.

Many developing countries supported the initiative. They highlighted the joint statement made by the three Director Generals of the WHO, the World Intellectual Property Organization (WIPO) and the WTO in June 2021 reaffirming their commitment to intensifying cooperation in support of access to medical technologies worldwide to tackle the COVID-19 pandemic, including vaccines, therapeutics and diagnostics. There was also a shared view that the negotiation process for the waiver extension should be open, inclusive and transparent.

Other members cautioned that more time was needed to conduct domestic consultations on a possible extension of the waiver to therapeutics and diagnostics. Some members also flagged the importance of an evidence-based negotiation as there was no evidence that intellectual property did indeed constitute a barrier to accessing COVID-19 vaccines. Some also reiterated the need for members to fully make use of all the flexibilities that already exist in the TRIPS Agreement (including compulsory licensing) before requesting new flexibilities.

The chair, Ambassador Lansana Gberie (Sierra Leone), asked members that were ready to engage to commence discussing this matter in various configurations. He encouraged members to individually report on progress to the General Council meeting on 25-26 July while some members may need more time to deliberate on the matter, he noted. The chair will inform members how best to structure discussions on this matter going forward, he added...

:::BMJ Global Health:::

June 2022 - Volume 7 - Suppl 3
Airborne diseases have plagued urban and rural communities alike in epidemic and pandemic forms since ancient times. During the 1918–1920 Spanish influenza pandemic, which was the deadliest in recorded history, it is estimated that more than 50 million people died. As of 1 May 2022, there have been over 510 million confirmed cases of SARS-CoV-2, a respiratory virus, and approximately 6.2 million deaths. Over the 2 years of pandemic, WHO has also estimated the excess mortality due to COVID-19, disease caused by SARS-CoV-2, to be 13.3–16.6 million deaths. Respiratory disease pandemics are clearly a threat to human security and development in our world.

The Eastern Mediterranean Region (EMR) is one of WHO’s six geographical regions and home to nearly 700 million people across 22 diverse countries and territories spread over South and West Asia, the Middle East and North Africa. A special issue series was commissioned in May 2021 jointly by the WHO Regional Office for the Eastern Mediterranean and BMJ Global Health to gather evidence on response and associated learnings from COVID-19 pandemic in the Region. This special issue explores the pandemic response with the aim of identifying successes, lessons and ways to address gaps for regional public health community to be able to better manage future pandemic risks. The Eastern Mediterranean Region is facing an unusual situation of multiple disease outbreaks ongoing in different countries (as shown in figure 1) along with the COVID-19 pandemic highlighting the importance of preparedness and response to epidemics and pandemics.

The special issue begins by providing a summary of COVID-19 pandemic response efforts in the region and discussing the lessons learnt while working towards the end of the ongoing pandemic. The key message is that in the challenging context of Eastern Mediterranean countries, science combined with systems, societies and sense of solidarity can not only stall the impact of this pandemic but also pave the way for a resilient future.

The overview of pandemic response is followed by a practice paper investigating how resilient hospitals, as part of health systems, worked and can work better in complex environments amid the pandemic. To build resilience in health systems and mitigate the spread of infectious diseases of consequence, bottom-up and top-down approaches are instrumental to strengthen collaboration between and among policy-makers, public health officials, health facility managers, frontline healthcare workers and communities. In order to improve public health practice and policy, COVID-19 pandemic is reminding us that we must build intrinsically adaptive healthcare systems that respond to the actual needs of the people they serve. Evaluation of COVID-19 response during tertiary care hospitals in Iraq provides an example of a recovering yet fragile context to reinforce the significance of building systems’ resilience.
The pandemic has seen an explosion of research on COVID-19, although research unrelated to COVID-19 has generally been neglected as remote work modalities posed limitations. Kaiyue et al have discussed research and knowledge management on COVID-19 and how integrating an innovative research pillar approach into WHO’s Incident Management structure has been assisting countries to integrate evidence into strategic, operational and policy decisions. The research pillar addressed three areas, that is, (1) enhancing capacity for evidence generation at national level, (2) timely provision of available evidence to support pandemic response and (3) enhancing capacity and experience sharing in use of evidence. The authors have called for enhancing research that addresses social measures and behaviour change as most national research studies have remained focused on therapeutics.

COVID-19 has given a stark reminder that in crisis situations such as the pandemic caused by a previously unknown pathogen, repurposing existing knowledge, resources and technology through innovation is a necessity. In this issue, a case study from Oman on contact tracing describes the efforts of the Oman Ministry of Health to institute a digital contact tracing system to detect clusters of cases and enforce notification, testing and isolation. Interestingly, the number of contacted cases decreased as the pandemic progressed, with fewer cases over time with effective contact tracing efforts. Similar patterns have been reported in other countries, which may reflect a maturity in response (due to more efficiency in targeting, or a result of the way the pandemic has progressed in the country) or may have due to fatigue and continued pressure on the health systems as the pandemic was sustained over time. In a paper from Lebanon, Farah et al have presented a case where field testing was adopted to demonstrate that timely development and implementation of a testing strategy is significant during epidemic response. Authors though cautioned that testing alone
will be insufficient if not complemented with contact tracing, risk communication and engagement with communities.

In the Eastern Mediterranean Region, low vaccine coverage has been attributed to limited supplies and weak immunisation systems. A case study from Djibouti presented in this issue shows how epidemiological data were used by the government to respond to a second surge in COVID-19 cases with deployment of vaccine. Since no one is safe until everyone is safe, international support is required to increase COVID-19 vaccination coverage, particularly in low-income and lower-middle-income countries.

As we move beyond the acute phase of the pandemic, it is likely that COVID-19 will attain endemic status. In a complex region such as the Eastern Mediterranean where conflict, frequent outbreaks, recurrent natural disasters and other vulnerabilities shape the daily lives of people and health systems, the COVID-19 pandemic has highlighted several lessons. Good planning and preparedness is key to responding quickly and effectively to pathogens of epidemic and pandemic potential, irrespective of the context, as it is for all emergencies. Contextual response needs more evidence and thus remedial strategies for example, in view of vital role of infection prevention and control in protecting human resources in already stressed and fragile environments. Global and regional solidarity for the equitable distribution of technical solutions (vaccines, diagnostics, therapeutics) is paramount for a speedy and effective response and recovery in pandemics, more so in compromised settings such as conflict zones. Responsible and decisive leadership at the highest levels of government is central to the effective control of COVID-19 pandemic, prevention of, preparedness for and response to the future pandemic threats.

::::
:::

**Featured Journal Content**

**medRxiv [pre-print]**
2022.07.05.22277269

**Drivers of COVID-19 policy stringency in 175 countries and territories: COVID-19 cases and deaths, gross domestic products per capita, and health expenditures**

doi: https://doi.org/10.1101/2022.07.05.22277269

**ABSTRACT**

Objective
To understand the associations of COVID-19 cases and deaths with policy stringency globally and regionally.

Methods
We modeled the marginal effects of new COVID-19 cases and deaths on policy stringency (scored 0–100) in 175 countries and territories, adjusting for gross domestic product (GDP) per capita and health expenditure (% of GDP). Time periods examined were March–August 2020, September 2020–February 2021, and March–August 2021.

Results
Policy response to new cases and deaths was faster and more stringent early in the COVID-19 pandemic (March–August 2020) compared to subsequent periods. New deaths were more strongly associated with stringent policies than new cases. In an average week, 1 new death per 100,000 people was associated with a stringency increase of 2.1 units in March–August 2020, 1.3 units in September 2020–February 2021, and 0.7 units in March–August 2021. New deaths in Africa and the Western Pacific were associated with more stringency than in other regions. Higher health expenditure was associated with less stringent policies. GDP per capita did not have consistent patterns of associations with stringency.

Conclusions
Our findings demonstrate the need for enhanced mortality surveillance to ensure policy alignment during health emergencies. Countries that invest less of their GDP in health are inclined to enact stringent policies during health emergencies than countries with more significant health expenditure.

Coronavirus [COVID-19] - WHO
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/diseases/novel-coronavirus-2019

Weekly Epidemiological and Operational updates
Last update: 17 Jun 2022
Confirmed cases :: 551 226 298
Confirmed deaths :: 6 345 595
Vaccine doses administered: 12 037 259 035

Weekly epidemiological update on COVID-19 – 6 July 2022
Overview
Globally, the number of new weekly cases increased for the fourth consecutive week after a declining trend since the last peak in March 2022.
During the week of 27 June to 3 July 2022, over 4.6 million cases were reported, a figure similar to that of the previous week. The number of new weekly deaths declined by 12% as compared to the previous week, with over 8100 fatalities reported.
As of 3 July 2022, over 546 million confirmed cases and over 6.3 million deaths have been reported globally.
In this edition, we provide an update on the circulating SARS-CoV-2 variants of concern (VOCs), including their geographic spread and prevalence. We also provide a summary of current evidence on the Omicron variant.
Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process 07 July 2022

[New additions; Full scale view available at title link above]

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 09 Jul 2022
An overview of information collected from publicly announced bilateral and multilateral supply agreements [no new agreements since 3/20/2022 reported]

Global Dashboard on COVID-19 Vaccine Equity
The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.

Dashboard on Vaccine Equity [accessed 09 Jul 2022]: https://data.undp.org/vaccine-equity/
See also visualization on Vaccine Access and Vaccine Affordability
COVID-19 Global Targets and Progress Tracker - IMF

The COVID-19 Global Targets and Progress Tracker presents a consolidated view of the progress towards global COVID-19 targets, barriers in access to COVID-19 tools, and delivery of donor pledges.

The global targets presented in the Tracker are based on an alignment of the targets identified in the IMF Pandemic Proposal, ACT-A Strategic Plan & Budget, and the US-hosted Global C19 Summit, and as such have been reaffirmed by multilateral institutions and global leaders. We will continue to enhance the tracker as we improve our data collection efforts.

**Daily Vaccination Rate Needed to Reach 70% by Mid-2022, assuming 2-dose vaccines (per 100 people)**

---

**COVID-19 Global Targets and Progress Tracker**

**High income countries: 3 in 4 people, or**

72.1% have been vaccinated with at least one dose as of Jul 6, 2022.

**Low income countries: 1 in 5 people, or**

20.06% have been vaccinated with at least one dose as of Jul 6, 2022.

**High income countries have to increase their health care spending by**

0.8% on average to cover cost of vaccinating 70% of the population.

**Low income countries have to increase their health care spending by**

56.6% on average to cover cost of vaccinating 70% of the population.

---

**Duke – Launch and Scale Speedometer**

**The Race for Global COVID-19 Vaccine Equity**
A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution [accessed 24 July 2021]

See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research

Overview of donations by top 10 donating countries

See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research
COVID Vaccines – OCHA:: HDX

COVID-19 Data Explorer: Global Humanitarian Operations

COVID-19 Vaccine Roll-out
09 Jul 2022 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA

Global COVID-19 Figures: 112M total confirmed cases; 2.3M total confirmed deaths
Global vaccines administered: 12.1B
Number of Countries: 28
COVAX Allocations Round 4-9 (Number of Doses): 170M
COVAX Delivered (Number of Doses): 330M
Other Delivered (Number of Doses): 350M
Total Delivered (Number of Doses): 680M
Total Administered (Number of Doses): 460M

Global COVID-19 Access Tracker
https://www.covid19globaltracker.org/

https://data.covid19taskforce.com/data

A global effort to help developing countries access and deliver COVID-19 vaccines, testing, and therapeutics, as they work to end the pandemic and boost economic recovery.
The International Monetary Fund, World Bank Group, World Health Organization and World Trade Organization have joined forces to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.


*Our World in Data*

**Coronavirus (COVID-19) Vaccinations**  [Accessed 09 Jul 2022]

:: 66.7% of the world population has received at least one dose of a COVID-19 vaccine.
:: 12.14 billion doses have been administered globally, and 5.54 million are now administered each day.
:: Only 20.2% of people in low-income countries have received at least one dose.
HHS

News

Biden-Harris Administration to make an additional 144,000 doses of JYNNEOS vaccine available to states and jurisdictions for monkeypox response

July 7, 2022 | News Release

FDA

Press Announcements

July 8, 2022 - FDA Roundup: July 8, 2022

Today, the FDA approved COMIRNATY (COVID-19 Vaccine, mRNA) for active immunization to prevent Coronavirus Disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in individuals 12 through 15 years of age. The approval follows a rigorous analysis and evaluation of the safety and effectiveness data conducted by FDA. The Pfizer-BioNTech COVID-19 Vaccine has been, and will continue to be, authorized for emergency use in this age group since May 2021. COMIRNATY (COVID-19 Vaccine, mRNA) has been approved for use in individuals 16 years of age and older since August 2021...

July 6, 2022 - Coronavirus (COVID-19) Update: FDA Authorizes Pharmacists to Prescribe Paxlovid with Certain Limitations

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

News & Press Releases

News: Further measures to identify and address medicine shortages during public health emergencies adopted (new) Last updated: 08/07/2022

On 7 July 2022, EMA’s Medicines Shortages Steering Group (MSSG) adopted the list of the main therapeutic groups of medicines used in emergency care, surgery and intensive care. The list forms the basis from which EMA will draw up concrete lists of critical medicines needed to deal with a specific ‘public health emergency’ or a ‘major event’1.

The medicines on such concrete lists are closely monitored because of a possible increased risk of shortages. If required, EMA can coordinate swift actions across Member States to ensure continued supply.

EMA recently published the first list of critical medicines focused on COVID-19 medicines.

This is a new responsibility that comes with the reinforced role of the Agency in crisis preparedness and management for medicines and medical devices to monitor shortages and ensure a robust response to major events or public health emergencies.
European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en

Latest Updates [Selected]

News
Weekly COVID-19 country overview
Epidemiological update - 8 Jul 2022

News
ECDC releases first update to its Rapid Risk Assessment on the monkeypox outbreak
News story - 8 Jul 2022

News
Joint ECDC-WHO/Europe monkeypox surveillance bulletin
Epidemiological update - 6 Jul 2022

News
Joint ECDC-WHO/Europe surveillance bulletin: Hepatitis of unknown origin in children
Epidemiological update - 30 Jun 2022

Publication
Monkeypox multi-country outbreak - first update
Risk assessment - 8 Jul 2022

Publication
Monkeypox outbreak: Resource toolkit for event organisers
Communication toolkit - 5 Jul 2022

Publication
Operational considerations for the provision of the HIV continuum of care for refugees from Ukraine in the EU/EEA
Guidance - 5 Jul 2022

Publication
Risk communication and community engagement approaches during the monkeypox outbreak in Europe, 2022
Technical guidance - 4 Jul 2022

European Commission
https://ec.europa.eu/commission/presscorner/home/en

Latest [Selected]
Press release 6 July 2022
Somalia: EU send Humanitarian Air Bridge to deliver life-saving aid
Due to the rapidly deteriorating security situation in Somalia, the EU is launching a Humanitarian Air Bridge, to delivering emergency supplies to hard-to-reach areas which are no longer accessible by road.

Africa: COVID-19 – Announcements/Regulatory Actions/Deployment
https://africacdc.org/covid-19-vaccination/

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment
Russia: Sputnik V – “the first registered COVID-19 vaccine”
https://sputnikvaccine.com/newsroom/pressreleases/

Press Releases
No new digest content identified.

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment
Ministry of Health and Family Welfare
https://www.mohfw.gov.in/
Government of India – Press Information Bureau

Latest Press Releases

COVID-19 Vaccination Update - Day 540
:: India’s cumulative vaccination coverage crosses 198.75 Crore
:: More than 8 lakh Vaccine doses administered today till 7 pm
Posted On: 09 JUL 2022 8:13PM by PIB Delhi

Indian Council for Medical Research (ICMR)
https://www.icmr.gov.in/media.html
Press Releases
No new digest content identified.

China: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

NHC minister meets with US ambassador to China
Updated: 2022-07-04
en.nhc.gov.cn

Ma Xiaowei, minister of China's National Health Commission (NHC), met with Nicholas Burns, the new United States ambassador to China, in Beijing on June 28 to exchange views on bilateral health communication and cooperation. Both sides expressed willingness to work together to implement the spirit of video conferences and telephone conversations between the two heads of state.

During the meeting, Ma introduced China’s COVID-19 prevention and control policies, stressing that China will continue to adhere to the dynamic zero-COVID policy and combat the virus with precise and scientific measures.

We did not identify any additional substantive, official announcements about China’s COVID response in general, or in Shanghai, Beijing or other China locations, leading us to include these reports/observations from the general media below. See China CDC below for additional announcements.

Beijing Introduces a Local Vaccine Pass and Urges Older People to Get Shots
Asia Pacific

The city announced the change months after other countries had put vaccine passports in place.
By Vivian Wang
NY Times, July 7, 2022
Millions tested in Shanghai as China grapples COVID resurgence
By Brenda Goh and Roxanne Liu
Summary
- Third day of mass testing in many Shanghai districts
- In a first, Beijing mandates vaccination proof for crowded venues
- China battles COVID outbreaks in several provinces
- Economy recovering, but foundation not solid, premier says

SHANGHAI/BEIJING, July 7 (Reuters) - Millions of people in Shanghai queued for a third day of mass COVID-19 testing on Thursday as authorities in several Chinese cities scrambled to stamp out new outbreaks that have rekindled worries about growth in the world's second-largest economy...

::: GPEI - Polio

Polio this week as of 06 July 2022
Headlines
:: Last week, the Global Commission for Certification of Poliomyelitis Eradication (GCC) met in-person in Geneva, to further review and evaluate global criteria for certification.
:: Following wide engagement of stakeholders – from lab workers to engineers to certification bodies responsible for signing off on the lockdown of poliovirus strains after certification of eradication – WHO’s chief guidance document for poliovirus containment has been given an overhaul. The update to the WHO Global Action Plan for Poliovirus Containment (GAP-IV, previously GAP-III) comes at the request of the WHO Containment Advisory Group (CAG) and streamlines the tool with other relevant WHO guidance and technical recommendations made by CAG. Its availability is expected to help accelerate containment implementation worldwide. Read more...

Summary of new polioviruses this week:
– Chad: three cVDPV2 cases
– Niger: one cVDPV2 case
– Nigeria: three cVDPV2 positive environmental samples
– Yemen: four cVDPV2 cases

::: UN OCHA – Current Emergencies
Current Corporate Emergencies
Afghanistan
Afghanistan: Flash Update #1 - Flash Flooding in Eastern and Central Regions (7 July 2022)

Northern Ethiopia
Ethiopia - Humanitarian Update Situation Report, 7 Jul 2022

Ukraine
Ukraine: Situation Report - Last updated: 08 July 2022
UN Report: Global hunger numbers rose to as many as 828 million in 2021

WHO and I-DAIR to partner for inclusive, impactful, and responsible international research in artificial intelligence (AI) and digital health

Launch of the COVID-19 impact on nutrition Analytical Framework

WHO Director-General welcomes ACT-Accelerator fair share contributions from Norway and Sweden

Preventing antimicrobial resistance together: Quadripartite announces WAAW 2022 theme

WHO and ESICM release COVID-19 critical care course for nurses and doctors

Vaccine manufacturers and regulators complete training on CTD format and requirements for vaccine dossiers to improve access in a WHO virtual workshop

WHO Director-General's remarks at Ground-breaking of new campus of AMREF International University – 9 July 2022
7 July 2022
Speech
WHO Director-General's opening remarks at the Member State Information Session on COVID-19 and other issues

[Excerpt]
Good morning, good afternoon and good evening to all Member States, and thank you for joining us once again.

Reported cases of COVID-19 have increased nearly 30% over the past two weeks. Four out of six of the WHO sub-regions saw cases increase in the last week. In Europe and America, BA.4 and BA.5 are driving waves. A new sub lineage of Omicron called BA.2.75 has also been detected, which we're following closely.

Compounding the challenge are a number of factors:
First, testing has reduced dramatically in many countries. This obscures the true picture of an evolving virus and the real burden of COVID-19 disease globally.

Second, new treatments, especially promising new oral antivirals, are still not reaching low- and low-middle income countries, depriving whole populations that need them.

Third, as the virus evolves, vaccines protection — while still really effective at preventing serious disease and death — does wane. Decreasing immunity underscores the importance of boosters, especially for the most at-risk.

Fourth, each wave of the virus leaves more people with a post-COVID condition, often referred to as long-COVID. Health systems are strained, and economies and societies are being disrupted.

Essential steps to take include:
One, vaccinate and boost those at most risk. This includes older people, people with chronic illnesses, the immunocompromised and health workers. Many of these groups remain unprotected in too many countries.

Two, make new oral antivirals and other treatments available to all. Working with Global Fund and UNICEF, WHO has developed an allocation mechanism to support countries as antivirals become available. However, our organizations are still trying to finalize the terms and conditions for low- and middle-income countries. Yesterday I called on Pfizer to work closely with us and with countries to ensure its new oral antiviral is available much more quickly...
WHO Regional Offices
Selected Press Releases, Announcements

WHO African Region
:: 07 July 2022  Ghana reports first-ever suspected cases of Marburg virus disease
:: 07 July 2022  Southern Africa in fresh vaccination drive to halt wild polio
:: 04 July 2022  The Democratic Republic of the Congo declares 14th Ebola outbreak over

WHO Region of the Americas  PAHO
:: 5 Jul 2022  With rising trends of syphilis and congenital syphilis in some countries in the Americas, PAHO calls for reinforcement of public health measures
In 2020, countries in the region reported 29,147 cases of congenital syphilis, and preliminary figures for 2021 indicate more than 30,000. If not detected and treated early, the disease can have devastating consequences to the fetus. Washington, DC, July 5, 2022 (PAHO)- With an increasing trend in cases of syphilis and congenital syphilis...

WHO South-East Asia Region  SEARO
No new digest content identified.

WHO European Region  EURO
:: 8 July 2022  News release
Health equity, a key priority of regional development strategies
:: 8 July 2022  News release
WHO launches a new initiative to place well-being at the heart of economic recovery

WHO Eastern Mediterranean Region  EMRO
:: Improving access to water brings hope amid drought in Somalia
6 July 2022
:: Polio outbreaks unfold in Yemen in midst of humanitarian crisis
6 July 2022

WHO Western Pacific Region
No new digest content identified.

Disease Outbreak News (DONs)
Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.

Ebola virus disease - Democratic Republic of the Congo
4 July 2022
Situation at a glance
On 4 July 2022, the Ministry of Health (MoH) of the Democratic Republic of the Congo declared the end of the Ebola virus disease (EVD) outbreak that affected Mbandaka and Wangata health zones, Equateur province. In accordance with WHO recommendations, the declaration was made 42 days
(twice the maximum incubation period) after the burial of the last confirmed case who died in the community.

WHO Events
https://www.who.int/news-room/events/1
[Selected]
Towards the development of a global CORE protocol for evaluation of treatments for hMPXV Leveraging the Congolese Experience
10 – 11 July 2022

New WHO Publications
https://www.who.int/publications/i
Selected Titles
8 July 2022
Public financial management for effective response to health emergencies
7 July 2022
Foresight approaches in global public health: a practical guide for WHO staff
7 July 2022
The research ethics review committee of WHO regional office for South-East Asia (SEARO-ERC)
Overview
These standard operating Procedures (“SOP”) delineate the structure, functions and process (including the review criteria) to be followed by the Research Ethics Review Committee of the WHO Regional Office for South-East Asia (SEARO) (the “Committee” or “SEARO-ERC”) for ethical review of research supported by SEARO or by any of its 11 country offices (WCOs). The SOP will override any other administrative rules or procedures1 specified elsewhere before March 2022. A new information circular will be issued to all the staff to inform them about these SOPs and other procedural issues.
6 July 2022
Contact tracing and quarantine in the context of COVID-19: interim guidance, 6 July 2022
5 July 2022
The Road to 2030
5 July 2022
Multi-sectoral impacts of the COVID-19 pandemic on nutrition outcomes: an analytical framework
Labcorp To Begin Monkeys in Testing Today, Doubling Nationwide Testing Capacity

Wednesday, July 6, 2022
Starting today, Labcorp will begin testing for monkeypox using CDC’s orthopoxvirus test (which detects all non-smallpox related orthopoxviruses, including monkeypox).

*****

ACIP Meetings

Next ACIP Meeting
October 19-20

*****

MMWR Weekly: Current Volume (71)
July 8, 2022 / No. 27
PDF of this issue
:: Factors Associated with Severe Outcomes Among Immunocompromised Adults Hospitalized for COVID-19 — COVID-NET, 10 States, March 2020–February 2022
:: Erratum: Vol. 71, No. 22: Use of JYNNEOS (Smallpox and Monkeypox Vaccine, Live, Nonreplicating) for Preexposure Vaccination of Persons at Risk for Occupational Exposure to Orthopoxviruses: :: Recommendations of the Advisory Committee on Immunization Practices — United States, 2022

*****

Coronavirus Disease 2019 (COVID-19)- CDC
Approximately 15 announcements/reports/data summaries.

*****

Africa CDC [to 09 Jul 2022]
http://www.africacdc.org/
News
African Union establishes One Health Coordination Group on Zoonotic Diseases
4 July 2022
To coordinate, support, monitor, and evaluate the implementation of the African Union One Health Strategy for Zoonotic Disease Prevention and Control across the Member States, the African Union Interagency Group on One Health has been established. The Interagency was established during a meeting on One Health that took place from 13-14 June 2022 at AU-IBAR in Nairobi, Kenya. The Interagency comprises several AU offices that have been mandated to deal with various aspects of human/animal health interventions, namely: The Africa Centre for Disease Control and Prevention (Africa CDC); The African Union InterAfrican Bureau for Animal Resources (AU-IBAR); The Scientific, Technical and Research Commission (STRC); The Department of Agriculture, Rural Development and Blue Economy (DARBE); The Department of Health, Humanitarian Affairs, and Social Development
(HHS); the InterAfrican Phytosanitary Council (AU-IAPSC); and the Citizens and Diaspora Organizations (CIDO)...

:::::

China CDC
http://www.chinacdc.cn/en/

National Health Commission of the People's Republic of China [to 09 Jul 2022]
http://en.nhc.gov.cn/
News
July 9: Daily briefing on novel coronavirus cases in China
On July 8, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 112 new cases of confirmed infections

NHC minister meets with US ambassador to China
Updated: 2022-07-04
en.nhc.gov.cn
Ma Xiaowei, minister of China’s National Health Commission (NHC), met with Nicholas Burns, the new United States ambassador to China, in Beijing on June 28 to exchange views on bilateral health communication and cooperation. Both sides expressed willingness to work together to implement the spirit of video conferences and telephone conversations between the two heads of state.
During the meeting, Ma introduced China’s COVID-19 prevention and control policies, stressing that China will continue to adhere to the dynamic zero-COVID policy and combat the virus with precise and scientific measures.

National Medical Products Administration – PRC [to 09 Jul 2022]
http://english.nmpa.gov.cn/
News
Chinese mainland reports 47 new local confirmed COVID-19 cases
2022-07-08
The Chinese mainland on Thursday reported 47 locally-transmitted confirmed COVID-19 cases, including 17 each in Shanghai and Anhui, the National Health Commission said Friday.

CCDC Weekly Reports: Current Volume (4)
2022-07-08 / No. 27 WORLD POPULATION DAY ISSUE
View PDF of this issue
:: Preplanned Studies: Towards Sustainable Development Goals: Study on the Consequences of Food Insecurity Among Global Population — Worldwide, 2022
:: Preplanned Studies: Adverse Childhood Experiences and Depressive Symptoms Trajectories Among Middle-Aged and Elderly — China, 2011–2018
:: Preplanned Studies: The Distribution and Potential Exposure Factors of Physical Activity Level Among Middle-Aged and Elderly Population — Six Communities, Beijing, China, October 2020 to January 2021
:: Commentary: Aging in China: Challenges and Opportunities
:: Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, April 2022
Organization Announcements

Editor's Note:
Careful readers will note that the number and range of organizations now monitored in our Announcements section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Paul G. Allen Frontiers Group  [to 09 Jul 2022]
https://alleninstitute.org/news-press/
News
No new digest content identified.

BMGF - Gates Foundation  [to 09 Jul 2022]
https://www.gatesfoundation.org/ideas/media-center
Press Releases and Statements
No new digest content identified.

Bill & Melinda Gates Medical Research Institute  [to 09 Jul 2022]
https://www.gatesmri.org/news
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people
No new digest content identified.

CARB-X  [to 09 Jul 2022]
https://carb-x.org/
News
07.08.2022
GARDP and CARB-X welcome renewed commitment by G7 leaders to address antimicrobial resistance
The Global Antibiotic Research and Development Partnership (GARDP) and Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) jointly welcome the recent G7 Leaders’ Communiqué, which acknowledges the rapid rise in antimicrobial resistance (AMR) globally and renews the commitment by G7 governments to address the most dangerous drug-resistant infections.

Center for Vaccine Ethics and Policy – GE2P2 Global Foundation  [to 09 Jul 2022]
https://centerforvaccineethicsandpolicy.net/
News/Analysis/Statements
:: Past weekly editions of Vaccines and Global Health: The Week in Review are available here.
:: Informed Consent: A Monthly Review – July 2022 is now posted [here](#)
:: Genomic Medicine Governance, Ethics, Policy: A Quarterly Review - May 2022 is now posted [here](#)

CEPI – Coalition for Epidemic Preparedness Innovations [to 09 Jul 2022]
http://cepi.net/

**Latest News**

Future-proofing the world against COVID-19 and other coronaviruses
- Dr Melanie Saville, CEPI’s top vaccine scientist, explores how the world can chart a long-term route out of the COVID-19 pandemic and beyond.

News 05 Jul 2022

CEPI funds consortium led by CPI to advance Caltech’s new all-in-one coronavirus vaccine
- Up to $30m funding will be provided to advance the technology that could protect against current and future SARS-CoV-2 variants and other SARS-like Betacoronaviruses.

05 Jul 2022

CEPI partners with Codiak BioSciences to develop broadly protective Betacoronavirus vaccine
- CEPI to provide up to US$2.5 million in seed funding to assess vaccine candidates from Codiak’s pan Betacoronavirus program through preclinical studies.

News 05 Jul 2022

DARPA – Defense Advanced Research Projects Agency [U.S.] [to 09 Jul 2022]
https://www.darpa.mil/news

News

No new digest content identified.

Duke Global Health Innovation Center [to 09 Jul 2022]
https://dukeghic.org/

Our Blog

No new digest content identified.

EDCTP [to 09 Jul 2022]
http://www.edctp.org/

The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials.

News

No new digest content identified.
Emory Vaccine Center  [to 09 Jul 2022]
http://www.vaccines.emory.edu/
Vaccine Center News
No new digest content identified.

European Vaccine Initiative  [to 09 Jul 2022]
http://www.euvaccine.eu/
Latest News, Events
No new digest content identified.

Evidence Aid  [to 09 Jul 2022]
Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.
http://www.evidenceaid.org/
Selected Resources
Sleep problems and COVID-19 (search up to February 2021)
Added July 9, 2022

Psychological impact of COVID-19 pandemic measures on inpatients with schizophrenia (search up to January 2021)
Added July 8, 2022

Expansion of the role of paramedics in the community
Added July 7, 2022

Fondation Merieux  [to 09 Jul 2022]
http://www.fondation-merieux.org/
News, Events
No new digest content identified

Gavi  [to 09 Jul 2022]
https://www.gavi.org/
News Releases
No new digest content identified

GHIT Fund  [to 09 Jul 2022]
https://www.ghitfund.org/newsroom/press
Press Releases
No new digest content identified

Global Fund  [to 09 Jul 2022]
Global Research Collaboration for Infectious Disease Preparedness [GloPID-R] [to 09 Jul 2022]
https://www.glopid-r.org/news/
News
No new digest content identified

Hilleman Laboratories  [to 09 Jul 2022]
http://www.hilleman-labs.org/
News & Insights
No new digest content identified

HHMI - Howard Hughes Medical Institute  [to 09 Jul 2022]
https://www.hhmi.org/news
Press Room
Research Jul 8 2022
DNA Typewriter Taps Out a Record Inside Cells
  To test their DNA typewriter, scientists sought to hide well-known phrases inside cells. But this invention’s most powerful application may lie in documenting the biological events that unfold within the boundaries of normal and diseased cells.

Human Vaccines Project  [to 09 Jul 2022]
http://www.humanvaccinesproject.org/
News
No new digest content identified.

IAVI  [to 09 Jul 2022]
https://www.iavi.org/
Latest News
FEATURES
July 6, 2022
Meet the IAVI scientist applying new and emerging technologies to one of the toughest challenges facing HIV vaccine researchers today

ICRC  [to 09 Jul 2022]
What’s New  [Selected]
Yemen: Women and girls struggle to access essential healthcare
Eight years into the armed conflict in Yemen, violence, economic hardship and deteriorating health services and health infrastructure increasingly keep women and girls from being able to access the essential healthcare they need.

07-07-2022 | News release

International Coalition of Medicines Regulatory Authorities [ICMRA]
Selected Statements, Press Releases, Research
Press Releases/Announcements
No new digest content identified.

IFFIm
http://www.iffim.org/
Press Releases/Announcements
No new digest content identified.

IFRC  [to 09 Jul 2022]
Press Releases [Selected]
Yemen: As global food insecurity crisis escalates, hope shrinks for millions already suffering from extreme hunger
08/07/2022 | Press release

Institut Pasteur  [to 09 Jul 2022]
Press Documents
No new digest content identified.

IOM / International Organization for Migration [to 09 Jul 2022]
News 05 Jul 2022
IOM, UNHCR and UNICEF Urge European States to End Child Detention

ISC / International Science Council  [to 09 Jul 2022]
https://council.science/current/
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.
News
Principles and values in international science cooperation
08.07.2022
Peter Gluckman gives the opening address to the Multilateral Dialogue on Principles and Values in International Research and Innovation Cooperation, hosted by The Research Directorate of the European Commission.

**International Union of Immunological Societies (IUIS)**
https://iuis.org/
*News/Events [Selected]*
No new digest content identified.

**IVAC** [to 09 Jul 2022]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
*Updates; Events*
No new digest content identified.

**IVI** [to 09 Jul 2022]
http://www.ivi.int/
*IVI News & Announcements*
No new digest content identified.

**Johns Hopkins Center for Health Security** [to 09 Jul 2022]
https://www.centerforhealthsecurity.org/news/center-news/
*Center News*
July 8, 2022

**MSF/Médecins Sans Frontières** [to 09 Jul 2022]
http://www.msf.org/
*Latest [Selected Announcements]*
*Ukraine*
**Supporting healthcare in a rural town in Ukraine**
Project Update 8 Jul 2022

*Nigeria*
**Out of sight: the neglected malnutrition crisis which threatens thousands of children’s lives**
Press Release 7 July 2022

*Iraq*
**Mosul: A slow road to recovery for the city of two springs**
Project Update 7 Jul 2022
**UNAIDS** [to 09 Jul 2022]
http://www.unaids.org/en
Selected Press Releases/Reports/Statements
No new digest content identified.

**UNHCR** Office of the United Nations High Commissioner for Refugees [to 09 Jul 2022]
Selected News Releases, Announcements
Global evaluation: International COVID-19 response fell short in upholding refugee rights
8 Jul 2022

**IOM, UNHCR and UNICEF urge European States to end child detention**
- New recommendations released by the three agencies offer solutions and alternatives to the continued practice of detaining asylum-seeking, refugee and migrant children across Europe.
5 Jul 2022

**UNICEF** [to 09 Jul 2022]
https://www.unicef.org/media/press-releases
Press Releases, News Notes, Statements [Selected]
Press release 06 July 2022
UN Report: Global hunger numbers rose to as many as 828 million in 2021
ROME/NEW YORK, 6 July 2022 - The number of people affected by hunger globally rose to as many as 828 million in 2021, an increase of about 46 million since 2020 and 150 million since the outbreak of the COVID-19 pandemic (1), according to a United Nations report that

**Unitaid** [to 09 Jul 2022]
https://unitaid.org/
Featured News
No new digest content identified.

**Vaccine Equity Cooperative [nee Initiative]** [to 09 Jul 2022]
https://vaccineequitycooperative.org/news/
News
No new digest content identified.

**Vaccination Acceptance & Demand Initiative [Sabin]** [to 09 Jul 2022]
https://www.vaccineacceptance.org/
Announcements, Blog
No new digest content identified.
**Vaccine Confidence Project** [to 09 Jul 2022]
http://www.vaccineconfidence.org/
*News, Research and Reports*

**Professor Heidi J. Larson nominated as a finalist for the Falling Walls Science Breakthroughs of the Year 2022**
6 July 2022

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 09 Jul 2022]
http://www.chop.edu/centers-programs/vaccine-education-center
*News*

*No new digest content identified.*

**Wellcome Trust** [to 09 Jul 2022]
https://wellcome.ac.uk/news
*News, Opinion, Reports*

**Explainer**

**Tracking the health effects of climate change around the world**
5 July 2022

4-minute read

Data is a powerful tool for understanding the health effects of climate change. That’s why we’ve mapped 120 years of climate data to show where four climate-related health risks (drought, flooding, extreme heat and disease) have been recorded. What’s crucial now is filling the gaps in the data so we can find ways to protect those communities most at risk.

**The Wistar Institute** [to 09 Jul 2022]
*Press Releases*

Jul. 7, 2022

**Collaboration Advances DNA-delivered Antibodies to Prevent COVID-19**

New synthetic nucleic acid approach seeks to use the body as the machinery for production of its own targeted protective antibodies.

**WFPHA: World Federation of Public Health Associations** [to 09 Jul 2022]
https://www.wfpha.org/
*Latest News - Blog*

*No new digest content identified.*

**World Bank** [to 09 Jul 2022]
*Selected News, Announcements*

**Careful Calibrations: Narrow Path for Global Recovery Requires Decisive Action**
The world economy is navigating uncharted waters as it continues to suffer from a series of destabilizing shocks. After more than two years of the COVID-19 pandemic, the war in Ukraine and its global effects...

Date: July 07, 2022 Type: Opinion

**African Heads of State Reaffirm Commitment to Recovering from Crises and Achieving Economic Transformation**

IDA20 financing and strong political leadership will be pivotal to recovery DAKAR, July 7, 2022 – African Heads of State and Government reaffirmed their commitment to seize key opportunities...

Date: July 07, 2022 Type: Press Release

**Dakar Call to Action**

An action plan to overcome crises and achieve economic transformation Following the Summit of the Heads of State and Government of Cabo Verde, Cameroon, Democratic Republic of Congo, Egypt, Ethiopia, Guinea...

Date: July 07, 2022 Type: Statement

**Unlocking Supply and Overcoming Hesitancy: Eastern and Southern Africa’s COVID-19 Vaccination Journey**

NA

Date: July 07, 2022 Type: Immersive Story

**A New Tool to Help Governments Evaluate Credit Risks Arising from Public Corporations**

The activities of public corporations can pose significant fiscal risks to governments. These risks can arise not only from explicit and implicit contingent liabilities (such as guaranteed and non-guaranteed...

Date: July 07, 2022 Type: Publication

**World Customs Organization – WCO** [to 09 Jul 2022]

http://www.wcoomd.org/

Latest News

06 July 2022

**IPR workshop for Customs administrations in the Latin America, Central America and Caribbean region**

The three-day workshop is designed to contribute to the effective and efficient implementation of the WCO’s Intellectual Property Rights (IPR) Strategy 2020.

**World Organisation for Animal Health (OIE)** [to 09 Jul 2022]

https://www.oie.int/en/

Press Releases, Statements

Editorial

**Crossing the species barrier: COVID-19, an example of reverse zoonosis**

Published on 6 July 2022
On World Zoonosis Day, the World Organisation for Animal Health (WOAH, founded as OIE) revisits 2021’s key events of COVID-19 in animals, most of them resulting from reverse zoonosis through close human contact with animals.

**WTO - World Trade Organisation** [to 09 Jul 2022]
http://www.wto.org/english/news_e/news_e.htm
*WTO News and Events [Selected]*
**DG Okonjo-Iweala: “The world expects us to keep delivering”**
7 July 2022
Speaking at an informal Heads of Delegation meeting on 7 July, WTO Director-General Ngozi Okonjo-Iweala welcomed the “Geneva package” concluded at the 12th Ministerial Conference (MC12) on 12-17 July but warned WTO members that they should not rest on their laurels. “We showed that we can deliver results for people across the globe,” she said. But “success begets expectations. Because of the unprecedented outcomes at MC12, the world expects us to keep delivering.”

**G20 economies show restraint in use of trade restrictions amidst ongoing instability**
7 July 2022
G20 economies continued to exercise restraint in the use of trade-restrictive measures despite increasing economic uncertainty aggravated by the COVID-19 pandemic and the war in Ukraine, according to the 27th WTO Trade Monitoring Report on G20 trade measures issued on 7 July. WTO Director-General Ngozi Okonjo-Iweala called on G20 countries, and WTO members at large, to show that the international community can work together to de-escalate tensions and ensure a solid economic recovery.

**TRIPS Council welcomes MC12 TRIPS waiver decision, discusses possible extension**
6 July 2022
At a meeting of the Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) on 6 July, WTO members welcomed the adoption of the TRIPS waiver decision on COVID-19 vaccines at the 12th Ministerial Conference (MC12) and began discussions on a possible extension to cover the production and supply of COVID-19 diagnostics and therapeutics. Trade officials also exchanged views on how to promote IP licensing to benefit small businesses, inventors and other individuals.
[See COVID Perspectives above for detail]

:::::

**ARM [Alliance for Regenerative Medicine]** [to 09 Jul 2022]
*Selected Press Releases*
*No new digest content identified.*

**BIO** [to 09 Jul 2022]
*Press Releases*
*No new digest content identified.*
International Council of Biotech Associations Announces New Board Leadership
Undated
The International Council of Biotech Associations (ICBA) is pleased to announce the election of its new board chair and vice chair. Oliver Schacht, Chairman of Bio Deutschland and CEO of OpGen Inc, was elected to serve as the new Chair, having served the previous term as Vice Chair. Claire Skentelbery, Director General of EuropaBio, was elected as the Vice Chair...

International Alliance of Patients’ Organizations – IAPO
Press and media [Selected]
No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]
No new digest content identified.

PhRMA
Latest News [Selected]
No new digest content identified.

Vaccines/Therapeutics/Medicines - Developer/Manufacturer Announcements

AstraZeneca
Press Releases - No new digest announcements identified
Bharat Biotech

Press Releases - No new digest announcements identified

BioCubaFarma – Cuba

Últimas Noticias - Website not leading at inquiry

Biological E

News - No new digest announcements identified

Biontech

Press Releases

Pfizer and BioNTech Announce U.S. FDA Approval of their COVID-19 Vaccine COMIRNATY® For Adolescents 12 through 15 Years of Age
8 Jul 2022

Pfizer and BioNTech Submit a Variation to EMA for the Vaccination of Children Ages 6 Months to less than 5 Years with COMIRNATY®
8 Jul 2022

CanSinoBIO

News - Website not responding at inquiry

CIGB

Latest News - No new digest announcements identified

Cinagen

Recent News - No new digest announcements identified

Clover Biopharmaceuticals - China

News - No new digest announcements identified

Curevac [Bayer Ag – Germany]

News - No new digest announcements identified

Gamaleya National Center

Latest News and Events - See Russia below.

GSK

Press releases for media

GSK gathers global experts to discuss role of vaccines in protecting people and the planet
7 July 2022, London UK

:: ‘Palio’ meeting, held annually by GSK, to address the growing threat to human health from infectious disease and its links to nature loss and climate change
:: Participants include Anthony Fauci (NIH), Muhammad Ali Pate (World Bank), Peter Dull (Gates Foundation), as well as CEPI, University of Oxford, PATH and Sabin Institute

GSK plc (LSE/NYSE: GSK) is convening leading experts in vaccines and sustainability at a scientific meeting on the theme ‘Vaccines for a sustainable planet’. 65 experts across immunology, vaccinology, epidemiology, and policy will gather on 7-8 July in Siena, Italy...
Novavax

Press Releases
Jul 7, 2022
Statement
Novavax Files in Switzerland for Expanded Conditional Marketing Authorization of Nuvaxovid™ COVID-19 Vaccine for Adolescents Aged 12 Through 17 and as a Booster in Individuals Aged 18 and Over

Jul 7, 2022
Statement
European Medicines Agency Approves SK bioscience as a Supplier of Novavax Nuvaxovid™ COVID-19 Vaccine

Jul 5, 2022
Novavax Nuvaxovid™ COVID-19 Vaccine Conditionally Authorized in the European Union for Adolescents Aged 12 Through 17

Pfizer

Recent Press Releases
07.08.2022
Updates and Statements
Pfizer and BioNTech Announce U.S. FDA Approval of their COVID-19 Vaccine COMIRNATY® For Adolescents 12 through 15 Years of Age

07.08.2022
Updates and Statements
Pfizer and BioNTech Submit a Variation to EMA for the Vaccination of Children 6 Months to less than 5 Years with COMIRNATY®

R-Pharm
https://rpharm-us.com/index.php
[No news or media page identified]

Sanofi Pasteur
Press Releases
July 4, 2022
Press releases
Sanofi Global Health launches nonprofit Impact® brand for 30 medicines in low-income countries
:: Medicines, including insulin, to be available in 40 lower-income countries
:: Investment fund established to help create sustainable health systems
:: Announcements comes as Global Health stakeholders gather in Paris

Serum Institute of India
NEWS & ANNOUNCEMENTS - No new digest announcements identified

Shifa Pharmed [Iran]
http://shafapharmed.com/
No news page identified.

Sinopharm/WIBPBIBP
News - No new digest announcements identified

Sinovac
Press Releases
SINOVAC joins hands with HKU-CTC research team and Gleneagles Hospital Hong Kong to kick off a clinical trial of an Omicron-specific inactivated vaccine for booster use in Hong Kong
2022/07/04

SK Biosciences
Press Releases - No new digest announcements identified

Valneva
Press Releases - No new digest announcements identified

Vector State Research Centre of Viralogy and Biotechnology
Home - No new digest announcements identified [404 error]

WestVac Biopharma
Media - No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]
Milestones, Perspectives

Monkeypox

Multi-country outbreak of monkeypox, External situation report #1 - 6 July 2022
Edition 1 6 July 2022 | Emergency Situational Updates
PDF: https://cdn.who.int/media/docs/default-source/2021-dha-docs/20220706_monkeypox_external_sitrep_final.pdf?sfvrsn=1b580b3d_4&download=true

Highlights

:: Updates on the multi-country outbreak of monkeypox has transitioned from the Disease Outbreak News to a biweekly situation report. The situation report will provide details such as the latest epidemiology, new guidance documents and updates on WHO advice. For information not included in this report, please see the Disease Outbreak News published on 27 June 2022.
:: WHO published a guidance document to provide public health advice for gatherings during the current monkeypox outbreak on 28 June. The advice was developed for host governments, public health authorities, national or international organizers, and professional staff involved in the planning and delivery of gatherings, including people organizing smaller gatherings or attending gatherings of any type and size.
:: The outbreak continues to primarily affect men who have sex with men who have reported recent sex with one or multiple male partners, suggesting no signal of sustained transmission beyond these networks for now.

Epidemiological Update

From 1 January to 4 July 2022, 6027 laboratory confirmed cases of monkeypox and three deaths have been reported to WHO from 59 countries/territories/areas in five WHO Regions (African Region, Region of the Americas, Eastern Mediterranean Region, European Region, Western Pacific Region) (Table 1). Since the previous Disease Outbreak News was published on 27 June 2022, 2614 new cases,
(77% increase) and two new deaths have been reported; nine new countries/territories/areas have reported cases. Ten countries have not reported new cases for over 21 days, the maximum duration of the incubation period of the disease. This is the first time that local transmission of monkeypox has been reported in newly-affected countries without epidemiological links to countries that have previously reported monkeypox in West or Central Africa...

---

**Featured Journal Content**

**Vaccine**

Volume 40, Issue 28  Pages 3813-3918 (21 June 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/28

Research article  Open access

**Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis**

Mark M. Janko, Jonah Joffe, Danielle Michael, Lauren Earl, ... Marcia R. Weaver
Pages 3903-3917

**Abstract**

**Background**

Rotavirus caused an estimated 151,714 deaths from diarrhea among children under 5 in 2019. To reduce mortality, countries are considering adding rotavirus vaccination to their routine immunization program. Cost-effectiveness analyses (CEAs) to inform these decisions are not available in every setting, and where they are, results are sensitive to modeling assumptions, especially about vaccine efficacy. We used advances in meta-regression methods and estimates of vaccine efficacy by location to estimate incremental cost-effectiveness ratios (ICERs) for rotavirus vaccination in 195 countries.

**Methods**

Beginning with Tufts University CEA and Global Health CEA registries we used 515 ICERs from 68 articles published through 2017, extracted 938 additional one-way sensitivity analyses, and excluded 33 ICERs for a sample of 1,418. We used a five-stage, mixed-effects, Bayesian metaregression framework to predict ICERs, and logistic regression model to predict the probability that the vaccine was cost-saving. For both models, covariates were vaccine characteristics including efficacy, study methods, and country-specific rotavirus disability-adjusted life-years (DALYs) and gross domestic product (GDP) per capita. All results are reported in 2017 United States dollars.

**Results**

Vaccine efficacy, vaccine cost, GDP per capita and rotavirus DALYs were important drivers of variability in ICERs. Globally, the median ICER was $2,289 (95% uncertainty interval (UI): $147–$38,993) and ranged from $85 per DALY averted (95% UI: $13–$302) in Central African Republic to $70,599 per DALY averted (95% UI: $11,030–$263,858) in the United States. Among countries eligible for support from Gavi, The Vaccine Alliance, the mean ICER was $255 per DALY averted (95% UI: $39–$918), and among countries eligible for the PAHO revolving fund, the mean ICER was $2,464 per DALY averted (95% UI: $382–$3,118).

**Conclusion**

Our findings incorporate recent evidence that vaccine efficacy differs across locations, and support expansion of rotavirus vaccination programs, particularly in countries eligible for support from Gavi, The Vaccine Alliance.
COVID Perspectives

TRIPS Council welcomes MC12 TRIPS waiver decision, discusses possible extension
WTO - 6 July 2022

At a meeting of the Council for Trade-Related Aspects of Intellectual Property Rights (TRIPS) on 6 July, WTO members welcomed the adoption of the TRIPS waiver decision on COVID-19 vaccines at the 12th Ministerial Conference (MC12) and began discussions on a possible extension to cover the production and supply of COVID-19 diagnostics and therapeutics. Trade officials also exchanged views on how to promote IP licensing to benefit small businesses, inventors and other individuals.

Discussion on the extension of COVID-19 IP waiver
At MC12, trade ministers adopted the Ministerial Decision on the TRIPS Agreement, which gives members greater scope to take direct action to diversify production of COVID-19 vaccines and to override the exclusive effect of patents through a targeted waiver over the next five years. It addresses specific problems identified during the pandemic and aims to help diversify vaccine production capacity. It also contains a commitment that no later than six months from the date of the decision (17 June), members will decide on its possible extension to cover the production and supply of COVID-19 diagnostics and therapeutics.

Many members took the floor to welcome the successful outcome at MC12, saying it proved that WTO members can put aside differences and work together to respond to the most urgent health challenges. A group of developing members who support an extension of the waiver to cover COVID-19 diagnostics and therapeutics circulated a proposal at the meeting including an indicative timeline for the TRIPS Council’s next steps in this regard.

These members argued that the waiver on COVID-19 vaccines falls short of their expectation and is not enough to help developing countries comprehensively address current and future health challenges. Equitable access to therapeutics and diagnostics, as pointed out by the World Health Organization (WHO), is critical in helping detect new cases and new variants. They said this waiver extension needs to be discussed with a sense of urgency given the fact that many least developed countries (LDCs) lack access to life-saving drugs and testing therapeutics.

Many developing countries supported the initiative. They highlighted the joint statement made by the three Director Generals of the WHO, the World Intellectual Property Organization (WIPO) and the WTO in June 2021 reaffirming their commitment to intensifying cooperation in support of access to medical technologies worldwide to tackle the COVID-19 pandemic, including vaccines, therapeutics and diagnostics. There was also a shared view that the negotiation process for the waiver extension should be open, inclusive and transparent.

Other members cautioned that more time was needed to conduct domestic consultations on a possible extension of the waiver to therapeutics and diagnostics. Some members also flagged the importance of an evidence-based negotiation as there was no evidence that intellectual property did indeed constitute a barrier to accessing COVID-19 vaccines. Some also reiterated the need for members to fully make
use of all the flexibilities that already exist in the TRIPS Agreement (including compulsory licensing) before requesting new flexibilities.

The chair, Ambassador Lansana Gberie (Sierra Leone), asked members that were ready to engage to commence discussing this matter in various configurations. **He encouraged members to individually report on progress to the General Council meeting on 25-26 July** while some members may need more time to deliberate on the matter, he noted. The chair will inform members how best to structure discussions on this matter going forward, he added...

::::::

::

**Featured Journal Content**

**BMJ Global Health**
June 2022 - Volume 7 - Suppl 3
https://gh.bmj.com/content/7/Suppl_3

**COVID-19 pandemic response in the WHO Eastern Mediterranean Region**

Editorial

COVID-19 pandemic response in one of the world’s most complex and vulnerable settings
(27 June, 2022)

Ziad A Memish, Richard John Brennan, Arash Rashidian, Abdinasir Abubakar, Wasiq Khan, Abdul Ghaffar

[Editor’s text bolding]

Airborne diseases have plagued urban and rural communities alike in epidemic and pandemic forms since ancient times. During the 1918–1920 Spanish influenza pandemic, which was the deadliest in recorded history, it is estimated that more than 50 million people died.1 As of 1 May 2022, there have been over 510 million confirmed cases of SARS-CoV-2, a respiratory virus, and approximately 6.2 million deaths.2 Over the 2 years of pandemic, WHO has also estimated the excess mortality due to COVID-19, disease caused by SARS-CoV-2, to be 13.3–16.6 million deaths.3 Respiratory disease pandemics are clearly a threat to human security and development in our world.

The Eastern Mediterranean Region (EMR) is one of WHO’s six geographical regions and home to nearly **700 million people across 22 diverse countries** and territories spread over South and West Asia, the Middle East and North Africa.4

A special issue series was commissioned in May 2021 jointly by the WHO Regional Office for the Eastern Mediterranean and BMJ Global Health to gather evidence on response and associated learnings from COVID-19 pandemic in the Region.4 **This special issue explores the pandemic response with the aim of identifying successes, lessons and ways to address gaps for regional public health community to be able to better manage future pandemic risks.**5 The Eastern Mediterranean Region is facing an unusual situation of multiple disease outbreaks ongoing in different countries (as shown in figure 1)6 along with the COVID-19 pandemic highlighting the importance of preparedness and response to epidemics and pandemics.

The special issue begins by providing a summary of COVID-19 pandemic response efforts in the region and discussing the lessons learnt while working towards the end of the ongoing pandemic. The key message is that in the challenging context of Eastern Mediterranean
countries, science combined with systems, societies and sense of solidarity can not only stall the impact of this pandemic but also pave the way for a resilient future.

The overview of pandemic response is followed by a practice paper investigating how resilient hospitals, as part of health systems, worked and can work better in complex environments amid the pandemic. To build resilience in health systems and mitigate the spread of infectious diseases of consequence, bottom-up and top-down approaches are instrumental to strengthen collaboration between and among policy-makers, public health officials, health facility managers, frontline healthcare workers and communities. In order to improve public health practice and policy, COVID-19 pandemic is reminding us that we must build intrinsically adaptive healthcare systems that respond to the actual needs of the people they serve. Evaluation of COVID-19 response during tertiary care hospitals in Iraq provides an example of a recovering yet fragile context to reinforce the significance of building systems’ resilience.

The pandemic has seen an explosion of research on COVID-19, although research unrelated to COVID-19 has generally been neglected as remote work modalities posed limitations. Kaiyue et al have discussed research and knowledge management on COVID-19 and how integrating an innovative research pillar approach into WHO’s Incident Management structure has been assisting countries to integrate evidence into strategic, operational and policy decisions. The research pillar addressed three areas, that is, (1) enhancing capacity for evidence generation at national level, (2) timely provision of available evidence to support pandemic response and (3) enhancing capacity and experience sharing in use of evidence. The authors have called for enhancing
research that addresses social measures and behaviour change as most national research studies have remained focused on therapeutics.

**COVID-19** has given a stark reminder that in crisis situations such as the pandemic caused by a previously unknown pathogen, repurposing existing knowledge, resources and technology through innovation is a necessity. In this issue, a case study from Oman on contact tracing describes the efforts of the Oman Ministry of Health to institute a digital contact tracing system to detect clusters of cases and enforce notification, testing and isolation. Interestingly, the number of contacted cases decreased as the pandemic progressed, with fewer cases over time with effective contact tracing efforts. Similar patterns have been reported in other countries, which may reflect a maturity in response (due to more efficiency in targeting, or a result of the way the pandemic has progressed in the country) or may have due to fatigue and continued pressure on the health systems as the pandemic was sustained over time. In a paper from Lebanon, Farah et al have presented a case where field testing was adopted to demonstrate that timely development and implementation of a testing strategy is significant during epidemic response. Authors though cautioned that testing alone will be insufficient if not complemented with contact tracing, risk communication and engagement with communities.

**In the Eastern Mediterranean Region, low vaccine coverage has been attributed to limited supplies and weak immunisation systems.** A case study from Djibouti presented in this issue shows how epidemiological data were used by the government to respond to a second surge in COVID-19 cases with deployment of vaccine. Since no one is safe until everyone is safe, international support is required to increase COVID-19 vaccination coverage, particularly in low-income and lower-middle-income countries.

**As we move beyond the acute phase of the pandemic, it is likely that COVID-19 will attain endemic status.** In a complex region such as the Eastern Mediterranean where conflict, frequent outbreaks, recurrent natural disasters and other vulnerabilities shape the daily lives of people and health systems, the COVID-19 pandemic has highlighted several lessons. Good planning and preparedness is key to responding quickly and effectively to pathogens of epidemic and pandemic potential, irrespective of the context, as it is for all emergencies. Contextual response needs more evidence and thus remedial strategies for example, in view of vital role of infection prevention and control in protecting human resources in already stressed and fragile environments. **Global and regional solidarity for the equitable distribution of technical solutions (vaccines, diagnostics, therapeutics) is paramount for a speedy and effective response and recovery in pandemics, more so in compromised settings such as conflict zones.** Responsible and decisive leadership at the highest levels of government is central to the effective control of COVID-19 pandemic, prevention of, preparedness for and response to the future pandemic threats.

:::}

---

**Featured Journal Content**

**medRxiv [pre-print]**
2022.07.05.22277269
Drivers of COVID-19 policy stringency in 175 countries and territories: COVID-19 cases and deaths, gross domestic products per capita, and health expenditures
doi: https://doi.org/10.1101/2022.07.05.22277269

ABSTRACT
Objective
To understand the associations of COVID-19 cases and deaths with policy stringency globally and regionally.

Methods
We modeled the marginal effects of new COVID-19 cases and deaths on policy stringency (scored 0–100) in 175 countries and territories, adjusting for gross domestic product (GDP) per capita and health expenditure (% of GDP). Time periods examined were March–August 2020, September 2020–February 2021, and March–August 2021.

Results
Policy response to new cases and deaths was faster and more stringent early in the COVID-19 pandemic (March–August 2020) compared to subsequent periods. New deaths were more strongly associated with stringent policies than new cases. In an average week, 1 new death per 100,000 people was associated with a stringency increase of 2.1 units in March–August 2020, 1.3 units in September 2020–February 2021, and 0.7 units in March–August 2021. New deaths in Africa and the Western Pacific were associated with more stringency than in other regions. Higher health expenditure was associated with less stringent policies. GDP per capita did not have consistent patterns of associations with stringency.

Conclusions
Our findings demonstrate the need for enhanced mortality surveillance to ensure policy alignment during health emergencies. Countries that invest less of their GDP in health are inclined to enact stringent policies during health emergencies than countries with more significant health expenditure.

* * * *

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 13, 2022 Issue 2
https://www.tandfonline.com/toc/uabr21/current
[Reviewed earlier]

AMA Journal of Ethics
Arts-Based Research in Health Care

Visual, musical, and poetic forms of creative expression have embodied healing in many cultures for millennia. Research methods based in these artistic forms have grown in prominence as the enterprise of health care has been led by kindred disciplines of bioethics and humanities to interrogate overmedicalization, to resist hyperfocus on measurability when the cost is neglect of narratives and experiences, and to recognize tendencies that too often privilege outcomes over processes. What we've learned is that medicine has much to learn from and contribute to the arts, and that the arts have much to learn from and contribute to medicine.

From the Editor

Arts-Based Research and Health Care

Mark Gilbert, PhD

Artistic or aesthetic ways of knowing have been embraced in many different cultures as forms of healing.1, 2 In health care and health professions education, there is increasing interest in the role of arts-based research or integrating the arts into a variety of clinical and community settings for therapeutic, educational, and expressive purposes.3, 4...

This special issue of the AMA Journal of Ethics presents myriad ways that artistic expression as a primary mode of inquiry can be used to nurture an inspiring medical education wherein creativity is embraced and can flourish.11 The clinicians, educators, artists, researchers, and students who contributed to this issue make clear how much health professionals and students can learn from engaging with artistic ways of knowing. Moreover, they testify to how the arts can be enriched and informed by health care. My experience of working in clinical contexts has taught me more about communication and silence. We hope this special issue creates opportunities for readers to witness the relationships and interactions fundamental to medicine and to grasp the profound challenges and abundant rewards that await all who engage in arts-based research in clinical, public health, and community contexts.

American Journal of Infection Control
June 2022 Volume 50 Issue 6 p593-716
http://www.ajicjournal.org/current
[Reviewed earlier]

American Journal of Preventive Medicine
June 2022 Volume 62 Issue 6 p807-964
https://www.ajpmonline.org/current
[Reviewed earlier]

American Journal of Public Health
June 2022 112(53)
http://ajph.aphapublications.org/toc/ajph/current
Supplement 3 2022
Public Health Nursing After COVID-19: Strengthening, Rebuilding, and Reimagining the System
This supplement issue of AJPH covers nursing and public health, offering insight into the importance of nurses during the COVID-19 pandemic as well as the future of nursing. Papers also engage with nursing and its intersection with climate change, vaccine readiness, community resilience, home visiting, and more. Additionally, images in this issue highlight a mobile produce market as well as a mural dedicated to the contributions of nurses from diverse backgrounds.

**American Journal of Tropical Medicine and Hygiene**
Volume 106 (2022): Issue 6 (Jun 2022)
https://www.ajtmh.org/view/journals/tpmd/106/6/tpmd.106.issue-6.xml
[Reviewed earlier]

**Annals of Internal Medicine**
June 2022 Volume 175, Issue 6
http://annals.org/aim/issue
[Reviewed earlier]

**Artificial Intelligence – An International Journal**
Volume 308 July 2022
[New issue; No digest content identified]

**BMC Cost Effectiveness and Resource Allocation**
http://resource-allocation.biomedcentral.com/
(Accessed 09 Jul 2022)
[No new digest content identified]

**BMJ Global Health**
June 2022 - Volume 7 - Suppl 3
https://gh.bmj.com/content/7/Suppl_3

*COVID-19 pandemic response in the WHO Eastern Mediterranean Region*

Merette Khalil, Awad Mataria, Hamid Ravaghi

*WHO’s support for COVID-19 research and knowledge management in the Eastern Mediterranean Region* (24 June, 2022)
Arash Rashidian, Kaiyue Wu, Lubna Al Ariqi, Eman Aly, Ahmed Mandil, Amal Barakat, Chiori Kodama, Mehrnaz Kheirandish, Hatem Nour Eldin Hassan, Henry Victor Doctor, Nilmini Hemachandra, Kamal Fahmy, Phillip Dingwall, Mohamed Nour, Sumithra Krishnamurthy Reddiar

*Epidemiology of the first and second waves of COVID-19 pandemic in Djibouti and the vaccination strategy developed for the response* (24 June, 2022)
Experience of field testing in Lebanon during the COVID-19 pandemic, January to August 2021 (24 June, 2022)
Mohamed Elhakim, Saleh Banoita Tourab, Fatouma Salem, Reinhilde Van De Weerdt

Commentary
COVID-19 pandemic response in the WHO Eastern Mediterranean Region (24 June, 2022)
Zeina Farah, Nada Ghosn, Tatiana Tohme, Hala Abou Naja, Reem Abdel Malak, Hawraa Sweidan, Hamad Hassan

Editorial
COVID-19 pandemic response in one of the world’s most complex and vulnerable settings (27 June, 2022)
Abdinasir Abubakar, Wasiq Khan, Hala Abou El Naja, Lubna Al Ariqi, Victoria D Bélorgeot, Stephanie J Hauck
[See Featured Journal Content above for detail]

BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 09 Jul 2022)
[No new digest content identified]

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 09 Jul 2022)
Gaps in measles vaccination coverage in Kasese district, Western Uganda: results of a qualitative evaluation
Despite the availability of a highly effective vaccine, measles remains a substantial public health problem in many countries including Uganda. In this study, conducted between June–August 2020 following a loc...
Authors: Abel Wilson Walekhwa, David Musoke, Aisha Nalugya, Claire Biribawa, Godfrey Nsereko, Solomon Tsebeni Wafula, Brenda Nakazibwe, Mary Nantongo, Doreen Awino Odera, Achangwa Chiara, Ross Mathew Boyce and Edgar Mugema Mulogo
Citation: BMC Infectious Diseases 2022 22:589
Content type: Research Published on: 4 July 2022

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 09 Jul 2022)
Ethical values and principles to guide the fair allocation of resources in response to a pandemic: a rapid systematic review
Authors: Lydia O'Sullivan, Edelweiss Aldasoro, Áine O'Brien, Maeve Nolan, Cliona McGovern and Áine Carroll
Abstract

Background
The coronavirus 2019 pandemic placed unprecedented pressures on healthcare services and magnified ethical dilemmas related to how resources should be allocated. These resources include, among others, personal protective equipment, personnel, life-saving equipment, and vaccines. Decision-makers have therefore sought ethical decision-making tools so that resources are distributed both swiftly and equitably. To support the development of such a decision-making tool, a systematic review of the literature on relevant ethical values and principles was undertaken. The aim of this review was to identify ethical values and principles in the literature which relate to the equitable allocation of resources in response to an acute public health threat, such as a pandemic.

Methods
A rapid systematic review was conducted using MEDLINE, EMBASE, Google Scholar, LitCOVID and relevant reference lists. The time period of the search was January 2000 to 6th April 2020, and the search was restricted to human studies. January 2000 was selected as a start date as the aim was to capture ethical values and principles within acute public health threat situations. No restrictions were made with regard to language. Ethical values and principles were extracted and examined thematically.

Results
A total of 1,618 articles were identified. After screening and application of eligibility criteria, 169 papers were included in the thematic synthesis. The most commonly mentioned ethical values and principles were: Equity, reciprocity, transparency, justice, duty to care, liberty, utility, stewardship, trust and proportionality. In some cases, ethical principles were conflicting, for example, Protection of the Public from Harm and Liberty.

Conclusions
Allocation of resources in response to acute public health threats is challenging and must be simultaneously guided by many ethical principles and values. Ethical decision-making strategies and the prioritisation of different principles and values needs to be discussed with the public in order to prepare for future public health threats. An evidence-based tool to guide decision-makers in making difficult decisions is required. The equitable allocation of resources in response to an acute public health threat is challenging, and many ethical principles may be applied simultaneously. An evidence-based tool to support difficult decisions would be helpful to guide decision-makers.

BMC Medicine
http://www.biomedcentral.com/bmcmed/content
(Accessed 09 Jul 2022)

Describing the population experiencing COVID-19 vaccine breakthrough following second vaccination in England: a cohort study from OpenSAFELY

While the vaccines against COVID-19 are highly effective, COVID-19 vaccine breakthrough is possible despite being fully vaccinated. With SARS-CoV-2 variants still circulating, describing the characteristics of...

Authors: Amelia Green, Helen Curtis, William Hulme, Elizabeth Williamson, Helen McDonald, Krishnan Bhaskaran, Christopher Rentsch, Anna Schultze, Brian MacKenna, Viyaasan Mahalingasivam, Laurie Tomlinson, Alex Walker, Louis Fisher, Jon Massey, Colm Andrews, Lisa Hopcroft...

Citation: BMC Medicine 2022 20:243
Content type: Research article Published on: 5 July 2022
COVID-19 vaccine hesitancy and patient self-advocacy: a statistical analysis of those who can and can’t get vaccinated
This study applies the Patient Self-Advocacy scale to investigate vaccine hesitancy in New Zealand. Due to New Zealand’s very limited tertiary hospital system and vulnerable populations, the Government’s strat...
Authors: Douglas Ashwell, Joanna Cullinane and Stephen M. Croucher
Citation: BMC Public Health 2022 22:1296
Content type: Research Published on: 5 July 2022

Disparities in the offer of COVID-19 vaccination to migrants and non-migrants in Norway: a cross sectional survey study
Vaccination is key to reducing the spread and impacts of COVID-19 and other infectious diseases. Migrants, compared to majority populations, tend to have lower vaccination rates, as well as higher infection di...
Authors: Esperanza Diaz, Jessica Dimka and Svenn-Erik Mamelund
Citation: BMC Public Health 2022 22:1288
Content type: Research Published on: 4 July 2022

BMJ Evidence-Based Medicine
June 2022 - Volume 27 - 3
https://ebm.bmj.com/content/27/3
[Reviewed earlier]

BMJ Open
June 2022 - Volume 12 - 6
https://bmjopen.bmj.com/content/12/6
[Reviewed earlier]
COVID-19 and investment in applied epidemiology
Matthew Myers Griffith, Amy Elizabeth Parry, Tambri Housen, Tony Stewart, Martyn D Kirk
Bull World Health Organ. 2022 Jul 1; 100(7): 415–415A. Published online 2022 Jul 1.
doi: 10.2471/BLT.22.288687
PMCID: PMC9243681

Systematic Reviews
Rapid diagnostic tests versus RT–PCR for Ebola virus infections: a systematic review and meta-analysis
Basilua Andre Muzembo, Kei Kitahara, Ayumu Ohno, Ngangu Patrick Ntontolo, Nlandu Roger Ngatu, Keinosuke Okamoto, Shin-Ichi Miyoshi
Bull World Health Organ. 2022 Jul 1; 100(7): 447–458. Published online 2022 Jun 1.
doi: 10.2471/BLT.21.287496
PMCID: PMC9243686

Perspectives
Child health, inclusive education and development
Bolajoko O Olusanya, Nem Yun Boo, Olaf Kraus de Camargo, Mijna Hadders-Algra, Donald Wertlieb, Adrian C Davis, on behalf of the Global Research on Developmental Disabilities Collaborators (GRDDC)
doi: 10.2471/BLT.22.288103
PMCID: PMC9243688

Cell
Jun 23, 2022  Volume 185  Issue 13  p2201-2390
https://www.cell.com/cell/current
[Reviewed earlier]

Child Care, Health and Development
Volume 48, Issue 4  Pages: 513-657  July 2022
https://onlinelibrary.wiley.com/toc/13652214/current
[Reviewed earlier]

Clinical Pharmacology & Therapeutics
Volume 112, Issue 1  Pages: 1-180  July 2022
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current
[New issue; No digest content identified]

Clinical Therapeutics
June 2022  Volume 44  Issue 6  p825-926
http://www.clinicaltherapeutics.com/current
Clinical Trials
Volume 19 Issue 3, June 2022
https://journals.sagepub.com/toc/ctja/19/3
[Reviewed earlier]

Conflict and Health
http://www.conflictandhealth.com/
[Accessed 09 Jul 2022]
[No new digest content identified]

Contemporary Clinical Trials
Volume 118 July 2022
https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/118/suppl/C
Short communication Full text access
Beyond privacy: A deeper understanding of the internet is required to protect digitized trial participants
Eric D. Perakslis
Article 106786

The CRISPR Journal
Volume 5, Issue 3 / June 2022
https://www.liebertpub.com/toc/crispr/5/3
[Reviewed earlier]

Current Genetic Medicine Reports
Volume 9, issue 4, December 2021
https://link.springer.com/journal/40142/volumes-and-issues/9-4
[Reviewed earlier]

Current Opinion in Infectious Diseases
June 2022 - Volume 35 - Issue 3
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
[New issue; No digest content identified]

Current Protocols in Human Genetics
Volume 108, Issue 1 December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current
[Reviewed earlier]
Developing World Bioethics
Volume 22, Issue 2 Pages: 63-122 June 2022
https://onlinelibrary.wiley.com/toc/14718847/current
[Reviewed earlier]

Development in Practice
Volume 32, Issue 4, 2022
http://www.tandfonline.com/toc/cdip20/current
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness
Volume 16 - Issue 3 - June 2022
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Reviewed earlier]

Disasters
Volume 46, Issue 3 Pages: 587-852 July 2022
https://onlinelibrary.wiley.com/toc/14677717/current
[Reviewed earlier]

EMBO Reports
Volume 23 Issue 6 7 June 2022
https://www.embopress.org/toc/14693178/current
[Reviewed earlier]

Emerging Infectious Diseases
Volume 28, Number 7—July 2022
http://wwwnc.cdc.gov/eid/
[Reviewed earlier]

Epidemics
Volume 39 June 2022
[Reviewed earlier]

Epidemiology and Infection
Volume 150 - 2022
https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue
[Reviewed earlier]
Ethics & Human Research
Volume 44, Issue 3  Pages: 1-40  May–June 2022
https://onlinelibrary.wiley.com/toc/25782363/current
Reviewing research app updates • Mental illness and IRB inclusiveness
[Reviewed earlier]

Ethics & International Affairs
Spring 2022 (36.1) | March 10, 2022
[Reviewed earlier]

Ethics, Medicine and Public Health
Volume 22  Pages 1-104 (June 2022)
[Reviewed earlier]

The European Journal of Public Health
Volume 32, Issue 3, June 2022
https://academic.oup.com/eurpub/issue/32/3
[Reviewed earlier]

Expert Review of Vaccines
Vol 21 (6) 2022
https://www.tandfonline.com/toc/ierv20/current
[Reviewed earlier]

Foreign Affairs
Volume 101, Number 3  May/June 2022
https://www.foreignaffairs.com/issues/2022/101/3
[Reviewed earlier]

Foreign Policy
Spring 2022
https://foreignpolicy.com/the-magazine/?issue_id=411130839
[Reviewed earlier]

Forum for Development Studies
Volume 49, 2022 - Issue 2
http://www.tandfonline.com/toc/sfds20/current
Socio-economic factors affecting high infant and child mortality rates in selected African countries: does globalisation play any role?

Despite the declining trends worldwide, infant and child mortality rates are still high in many African countries. These high rates are problematic; therefore, this study attempts to explore the contributing factors that cause high infant and child mortality rates in 14 African countries using panel data for the period of 2000–2018. In particular, the role globalisation is explored.
Authors: Mohammad Mafizur Rahman, Khosrul Alam and Rasheda Khanam
Content type: Research 7 July 2022

**Health and Human Rights**
Volume 24, Issue 1, June 2022
[Reviewed earlier]

**Health Economics, Policy and Law**
Volume 17 - Issue 3 - July 2022
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]

**Health Policy and Planning**
Volume 37, Issue 6, June 2022
https://academic.oup.com/heapol/issue/37/6
[Reviewed earlier]

**Health Research Policy and Systems**
http://www.health-policy-systems.com/content
[Accessed 09 Jul 2022]
[No new digest content identified]

**Human Gene Therapy**
Volume 33, Issue 11-12 / June 2022
https://www.liebertpub.com/toc/hum/33/11-12
[Reviewed earlier]

**Humanitarian Practice Network**
https://odihpn.org/
*Featured Publications*
[No new digest content identified]

**Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)
Volume 18, Issue 5, 2022
https://www.tandfonline.com/toc/khvi20/18/5?nav=tocList
[Reviewed earlier]

**Immunity**
Jun 14, 2022  Volume 55  Issue 6  p925-1138
Combating the global spread of poverty-related Monkeypox outbreaks and beyond

The current unprecedented Monkeypox outbreaks emergence and spread on non-endemic countries has led to over 3413 laboratory confirmed cases and one death, and yet, does not constitute a public health emergency...

Authors: Ernest Tambo and Ashwaq M. Al-Nazawi

Citation: Infectious Diseases of Poverty 2022 11:80

Content type: Editorial Published on: 7 July 2022
This modeling study estimates the excess deaths attributable to COVID-19 disease in Massachusetts during the Delta (June to December 2021) and Omicron (December 2021 to February 2022) waves.

These articles on COVID-19 were published across the JAMA Network in the last week.
Journal of Development Economics
Volume 157  June 2022
[Reviewed earlier]

Journal of Empirical Research on Human Research Ethics
Volume 17 Issue 3, July 2022
http://journals.sagepub.com/toc/jre/current
[Reviewed earlier]

Journal of Epidemiology & Community Health
June 2022 - Volume 76 - 6
https://jech.bmj.com/content/76/6
[New issue; No digest content identified]

Journal of Evidence-Based Medicine
Volume 15, Issue 1  Pages: 1-72  March 2022
https://onlinelibrary.wiley.com/toc/17565391/current
[Reviewed earlier]

Journal of Global Ethics
Volume 18, Issue 1, 2022
http://www.tandfonline.com/toc/rjge20/current
Special Issue: Relational Theory: Feminist Approaches, Implications, and Applications
Guest Editors Christine M. Koggel, Ami Harbin and Jennifer J. Llewellyn
[Reviewed earlier]

Journal of Health Care for the Poor and Underserved (JHCPU)
Volume 33, Number 2, May 2022
https://muse.jhu.edu/issue/47787
Table of Contents
[Reviewed earlier]

Journal of Immigrant and Minority Health
Volume 24, issue 3, June 2022
https://link.springer.com/journal/10903/volumes-and-issues/24-3
Contents
[Reviewed earlier]
Journal of Immigrant & Refugee Studies
Volume 20, 2022 , Issue 3
https://www.tandfonline.com/toc/wimm20/current
[New issue; No digest content identified]

Journal of Infectious Diseases
Volume 225, Issue 12, 15 June 2022
https://academic.oup.com/jid/issue/225/12
[Reviewed earlier]

Journal of International Development
Volume 34, Issue 4  Pages: 693-930  May 2022
https://onlinelibrary.wiley.com/toc/10991328/current
Special Issue: Long run effects of Covid-19 on developing countries
Issue Edited by: Sanghamitra Bandyopadhyay, Krishna Vadlamannati
[Reviewed earlier]

Journal of Medical Ethics
July 2022 - Volume 48 - 7
http://jme.bmj.com/content/current
Current controversy
WHO’s allocation framework for COVAX: is it fair? (9 April, 2021) Free
Siddhanth Sharma, Nisrine Kawa, Apoorva Gomber

Original research
Challenges to biobanking in LMICs during COVID-19: time to reconceptualise research ethics guidance for pandemics and public health emergencies? (12 May, 2021)
Shenuka Singh, Rosemary Jean Cadigan, Keymanthri Moodley

Journal of Patient-Centered Research and Reviews
Volume 9, Issue 2 (2022)
https://institutionalrepository.aah.org/jpcrr/
[Reviewed earlier]

Journal of Pediatrics
July 2022  Volume 246  p1-294
http://www.jpeds.com/current
[Reviewed earlier]
Journal of Pharmaceutical Policy and Practice
https://joppp.biomedcentral.com/
[Accessed 09 Jul 2022]
[No digest content identified]

Journal of Public Health Management & Practice
May/June 2022 - Volume 28 - Issue 3
https://journals.lww.com/jphmp/pages/currenttoc.aspx
[Reviewed earlier]

Journal of Public Health Policy
Volume 43, issue 2, June 2022
[Reviewed earlier]

Journal of Refugee & Global Health
Volume 4, Issue 1 (2021)
https://ir.library.louisville.edu/rgh/
[Reviewed earlier]

Journal of the Royal Society – Interface
July 2022  Volume 19  Issue 192
https://royalsocietypublishing.org/toc/rsif/current
[New issue; No digest content identified]

Journal of Travel Medicine
Volume 29, Issue 3, April 2022
https://academic.oup.com/jtm/issue
[Reviewed earlier]

Journal of Virology
Volume 96  Number 12  June 2022
http://jvi.asm.org/content/current
[Reviewed earlier]

The Lancet
Jul 09, 2022  Volume 400  Number 10346  p73-136
https://www.thelancet.com/journals/lancet/issue/current
Comment
COVID-19 vaccination for children aged 5–11 years
Shamez N Ladhani
Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5–11 years in Italy: a retrospective analysis of January–April, 2022

Chiara Sacco, et al. on behalf of the Italian National COVID-19 Integrated Surveillance System and the Italian COVID-19 vaccines registry

Summary

Background
By April 13, 2022, more than 4 months after the approval of BNT162b2 (Pfizer–BioNTech) for children, less than 40% of 5–11-year-olds in Italy had been vaccinated against COVID-19. Estimating how effective vaccination is in 5–11-year-olds in the current epidemiological context dominated by the omicron variant (B.1.1.529) is important to inform public health bodies in defining vaccination policies and strategies.

Methods
In this retrospective population analysis, we assessed vaccine effectiveness against SARS-CoV-2 infection and severe COVID-19, defined as an infection leading to hospitalisation or death, by linking the national COVID-19 surveillance system and the national vaccination registry. All Italian children aged 5–11 years without a previous diagnosis of infection were eligible for inclusion and were followed up from Jan 17 to April 13, 2022. All children with inconsistent vaccination data, diagnosed with SARS-CoV-2 infection before the start date of the study or without information on the municipality of residence were excluded from the analysis. With unvaccinated children as the reference group, we estimated vaccine effectiveness in those who were partly vaccinated (one dose) and those who were fully vaccinated (two doses).

Findings
By April 13, 2022, 1 063 035 (35·8%) of the 2 965 918 children aged 5–11 years included in the study had received two doses of the vaccine, 134 386 (4·5%) children had received one dose only, and 1 768 497 (59·6%) were unvaccinated. During the study period, 766 756 cases of SARS-CoV-2 infection and 644 cases of severe COVID-19 (627 hospitalisations, 15 admissions to intensive care units, and two deaths) were notified. Overall, vaccine effectiveness in the fully vaccinated group was 29·4% (95% CI 28·5–30·2) against SARS-CoV-2 infection and 41·1% (22·2–55·4) against severe COVID-19, whereas vaccine effectiveness in the partly vaccinated group was 27·4% (26·4–28·4) against SARS-CoV-2 infection and 38·1% (20·9–51·5) against severe COVID-19. Vaccine effectiveness against infection peaked at 38·7% (37·7–39·7) at 0–14 days after full vaccination and decreased to 21·2% (19·7–22·7) at 43–84 days after full vaccination.

Interpretation
Vaccination against COVID-19 in children aged 5–11 years in Italy showed a lower effectiveness in preventing SARS-CoV-2 infection and severe COVID-19 than in individuals aged 12 years and older. Effectiveness against infection appears to decrease after completion of the current primary vaccination cycle.
Lancet Digital Health
Jun 2022 Volume 4 Number 6 e398-e476
https://www.thelancet.com/journals/landig/issue/current
Articles
[Reviewed earlier]

Lancet Global Health
Jun 2022 Volume 10 Number 6 e773-e926
https://www.thelancet.com/journals/langlo/issue/current
[Reviewed earlier]

Lancet Infectious Diseases
Jun 2022 Volume 22 Number 6 p743-912, e159-e182
https://www.thelancet.com/journals/laninf/issue/current
[Reviewed earlier]

Lancet Public Health
Jun 2022 Volume 7 Number 6 e485-e572
https://www.thelancet.com/journals/lanpub/issue/current
[Reviewed earlier]

Lancet Respiratory Medicine
Jun 2022 Volume 10 Number 6 p525-622, e51-e60
https://www.thelancet.com/journals/lanres/issue/current
[Reviewed earlier]

Maternal and Child Health Journal
Volume 26, issue 6, June 2022
https://link.springer.com/journal/10995/volumes-and-issues/26-6
[Reviewed earlier]

Medical Decision Making (MDM)
Volume 42 Issue 5, July 2022
http://mdm.sagepub.com/content/current
[Reviewed earlier]

The Milbank Quarterly
A Multidisciplinary Journal of Population Health and Health Policy
Volume 100, Issue 2 Pages: 315-616 June 2022
https://onlinelibrary.wiley.com/toc/14680009/current
[Reviewed earlier]
Whole-genome sequencing reveals host factors underlying critical COVID-19

Whole-genome sequencing, transcriptome-wide association and fine-mapping analyses in over 7,000 individuals with critical COVID-19 are used to identify 16 independent variants that are associated with severe illness in COVID-19.

Athanasios Kousathanas, Erola Pairo-Castineira, J. Kenneth Baillie

Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2

Isolates of authentic SARS-CoV-2 variants BA.1 and BA.2 exhibit similar infectivity and pathogenicity and show susceptibility to neutralizing therapeutic antibodies and antiviral compounds in mouse and hamster models.

Ryuta Uraki, Maki Kiso, Yoshihiro Kawaoka
**The Vaccine-Hesitant Moment**
H.J. Larson, E. Gakidou, and C.J.L. Murray

Vaccine hesitancy is a state of indecision and uncertainty about vaccination before a decision is made to act (or not act). It represents a time of vulnerability and opportunity. Multiple surveys that were conducted to examine the sentiments concerning coronavirus disease 19 (Covid-19) vaccination have exposed new levels of volatility around vaccine hesitancy, particularly when the hesitancy is powered by digital media platforms. Spikes in vaccine hesitancy often coincide with new information, new policies, or newly reported vaccine risks. Some of the variability is due to factors such as a decline in the public’s trust of experts, preferences for alternative health, political polarization, and belief-based extremism. In this review, we use the examples of hesitancy regarding the measles–mumps–rubella (MMR), human papillomavirus (HPV), and Covid-19 vaccines to look at the multifaceted issues that fuel vaccine hesitancy. Each of these examples is part of a larger, complex story...

**Editorials**

**Audio Interview: Designing the Next Covid-19 Vaccine**
E.J. Rubin, L.R. Baden, and S. Morrissey

**npj Vaccines**
https://www.nature.com/npjvaccines/
[Accessed 09 Jul 2022]

**Article**

*Open Access*  Published: 06 July 2022
Comparative analysis of human immune responses following SARS-CoV-2 vaccination with BNT162b2, mRNA-1273, or Ad26.COV2.S
Dominique J. Barbeau, Judith M. Martin, Anita K. McElroy

Pediatrics
Volume 150, Issue 1 July 2022
https://publications.aap.org/pediatrics/issue/150/1

Human Papillomavirus Vaccination Trends Among Adolescents: 2015 to 2020
Peng–jun Lu, MD, PhD; David Yankey, MS, PhD; Benjamin Fredua, MS; Mei–Chun Hung, MPH, PhD; Natalie Sterrett, MPH ...

PharmacoEconomics
Volume 40, issue 7, July 2022
https://link.springer.com/journal/40273/volumes-and-issues/40-7
[New issue; No digest content identified]

PLoS Biology
https://journals.plos.org/plosbiology/
(Accessed 09 Jul 2022)

Consensus View
Recommendations for empowering early career researchers to improve research culture and practice
| published 07 Jul 2022 PLOS Biology
https://doi.org/10.1371/journal.pbio.3001680

Abstract
Early career researchers (ECRs) are important stakeholders leading efforts to catalyze systemic change in research culture and practice. Here, we summarize the outputs from a virtual unconventional conference (unconference), which brought together 54 invited experts from 20 countries with extensive experience in ECR initiatives designed to improve the culture and practice of science. Together, we drafted 2 sets of recommendations for (1) ECRs directly involved in initiatives or activities to change research culture and practice; and (2) stakeholders who wish to support ECRs in these efforts. Importantly, these points apply to ECRs working to promote change on a systemic level, not only those improving aspects of their own work. In both sets of recommendations, we underline the importance of incentivizing and providing time and resources for systems-level science improvement activities, including ECRs in organizational decision-making processes, and working to dismantle structural
barriers to participation for marginalized groups. We further highlight obstacles that ECRs face when working to promote reform, as well as proposed solutions and examples of current best practices.

**PLoS Genetics**
https://journals.plos.org/plosgenetics/
(Accessed 09 Jul 2022)
[No new digest content identified]

**PLoS Medicine**
http://www.plosmedicine.org/
(Accessed 09 Jul 2022)
[No new digest content identified]

**PLoS Neglected Tropical Diseases**
http://www.plosntds.org/
(Accessed 09 Jul 2022)
[No new digest content identified]

**PLoS One**
http://www.plosone.org/
[Accessed 09 Jul 2022]
Research Article
**COVID-19 vaccine hesitancy in Malaysia: Exploring factors and identifying highly vulnerable groups**
Adi Jafar, Ramzah Dambul, Ramli Dollah, Nordin Sakke, Mohammad Tahir Mapa, Eko Prayitno Joko
Research Article | published 08 Jul 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0270868

**How many people is the COVID-19 pandemic pushing into poverty? A long-term forecast to 2050 with alternative scenarios**
Jonathan D. Moyer, Willem Verhagen, Brendan Mapes, David K. Bohl, Yutang Xiong, Vivian Yang, Kaylin McNeil, José Solórzano, Mohammad Irfan, Cade Carter, Barry B. Hughes
Research Article | published 08 Jul 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0270846

**The level and determinants of COVID-19 vaccine acceptance in Ghana**
Grace Adjei Okai, Gordon Abekah-Nkrumah
Research Article | published 08 Jul 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0270768

**Facilitators and barriers to COVID-19 vaccination uptake among ethnic minorities: A qualitative study in primary care**
Lucia Magee, Felicity Knights, Doug G. J. Mckechnie, Roaa Al-bedaery, Mohammad S. Razai
Research Article | published 08 Jul 2022 PLOS ONE
Message framing and COVID-19 vaccine acceptance among millennials in South India
Aslesha Prakash, Robert Jeyakumar Nathan, Sannidhi Kini, Vijay Victor
Research Article | published 08 Jul 2022 PLOS ONE
https://doi.org/10.1371/journal.pone.0269487

PLoS Pathogens
http://journals.plos.org/plospathogens/
[Accessed 09 Jul 2022]
[No new digest content identified]

PNAS - Proceedings of the National Academy of Sciences of the United States
June 28, 2022 | vol. 119 | no. 26
https://www.pnas.org/toc/pnas/119/26
[New issue; No digest content identified]

Prehospital & Disaster Medicine
Volume 37 - Issue 3 - June 2022
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]

Preventive Medicine
Volume 159 June 2022
https://www.sciencedirect.com/journal/preventive-medicine/vol/159/suppl/C
[Reviewed earlier]

Proceedings of the Royal Society B
13 July 2022  Volume 289 Issue 1978
https://royalsocietypublishing.org/toc/rspb/current
[New issue; No digest content identified]

Public Health
Volume 207  Pages e1-e6, 1-128 (June 2022)
[Reviewed earlier]

Public Health Ethics
Volume 15, Issue 1, April 2022
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]
Public Health Reports
Volume 137 Issue 3, May/June 2022
https://journals.sagepub.com/toc/phrg/137/3
[Reviewed earlier]

Qualitative Health Research
Volume 32 Issue 7, June 2022
https://journals.sagepub.com/toc/qhra/current
[New issue; No digest content identified]

Research Ethics
Volume 18 Issue 3, July 2022
http://journals.sagepub.com/toc/reab/current
[Reviewed earlier]

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 09 Jul 2022]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
[No new digest content identified]

Risk Analysis
Volume 42, Issue 6  Pages: 1149-1364  June 2022
https://onlinelibrary.wiley.com/toc/15396924/current
Special Issue: Bayesian Networks for Risk Analysis and Decision Support
[New issue; No digest content identified]

Risk Management and Healthcare Policy
[Accessed 09 Jul 2022]
[No new digest content identified]

Science
Volume 377| Issue 6602| 8 Jul 2022
The rapid replacement of the SARS-CoV-2 Delta variant by Omicron (B.1.1.529) in England
BY Robert S. Paton, Christopher E. Overton, Thomas Ward
06 Jul 2022 Open Access

The Omicron variant replaced the Delta variant in England despite the rate of replacement approximately halving in mid-December 2021.

Abstract
The emergence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.529 (Omicron) variant caused international concern due to its rapid spread in Southern Africa. It was unknown whether this variant would replace or coexist with (...)

Multimorbidity patterns and function among adults in low- and middle-income countries: a scoping review protocol

A fifth of adults in low- and middle-income countries (LMICs) have multimorbid conditions, which are linked to socio-economic deprivation and aging. Multimorbidity is associated with high rates of functional p...

Authors: Karina Berner, Nassib Tawa and Quinette Louw
Citation: Systematic Reviews 2022 11:139
Content type: Protocol Published on: 7 July 2022
Travel Medicine and Infectious Diseases
Volume 47   May–June 2022
[Reviewed earlier]

Tropical Medicine & International Health
Volume 27, Issue 6   Pages: i-iv, 545-601   June 2022
https://onlinelibrary.wiley.com/toc/13653156/current
[Reviewed earlier]

Vaccine
Volume 40, Issue 29   Pages 3919-3984 (23 June 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/29
Discussion   Full text access
Working towards a sustainable, healthy market for vaccines: A framework to support evidence-based policymaking
Marina Rodes-Sanchez, Julia Spencer, Anupama Tantri, Rachel Mitrovich, ... Lotte Steuten
Pages 3919-3922

Discussion   Full text access
Between persuasion and compulsion: The case of COVID-19 vaccination in Canada
Eve Dubé, Dominique Gagnon, Noni MacDonald
Pages 3923-3926

Research article   Abstract only
Factors associated with caregivers’ hesitancy to vaccinate children against influenza: A cross-sectional survey in China
Xiaozhen Lai, Mengyao Li, Zhiyuan Hou, Jia Guo, ... Hai Fang
Pages 3975-3983

Vaccine
Volume 40, Issue 28   Pages 3813-3918 (21 June 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/28
Discussion   Full text access
Moving vaccination beyond partisan politics
Beth L. Hoffman, Tina Batra Hershey, Kar-Hai Chu, Jaime E. Sidani
Pages 3815-3817

Research article   Full text access
Measuring parents’ readiness to vaccinate themselves and their children against COVID-19
Franziska Rees, Mattis Geiger, Lau Lilleholt, Ingo Zettler, ... Oliver Wilhelm
Pages 3825-3834

Research article   Full text access
Risk-based cost-benefit analysis of alternative vaccines against COVID-19 in Brazil: Coronavac vs. Astrazeneca vs. Pfizer
Paulo Gabriel Siqueira, Heitor Oliveira Duarte, Márcio das Chagas Moura
Pages 3851-3860

Research article  Open access
Cost-effectiveness of rotavirus vaccination in children under five years of age in 195 countries: A meta-regression analysis
Mark M. Janko, Jonah Joffe, Danielle Michael, Lauren Earl, ... Marcia R. Weaver
Pages 3903-3917

Vaccine
Volume 40, Issue 27  Pages 3721-3812 (15 June 2022)
https://www.sciencedirect.com/journal/vaccine/vol/40/issue/27
Research article  Abstract only
Preventing erosion of oral polio vaccine acceptance: A role for vaccinator visits and social norms
Gillian K. SteeFisher, Hannah Caporello, Ross McIntosh, Rana Muhammad Safdar, ... Robert J. Blendon
Pages 3752-3760

Research article  Abstract only
Development of effective messages to promote maternal immunization in Kenya
Paula M. Frew, Ines Gonzalez-Casanova, Nancy A. Otieno, Fauzia A. Malik, ... Saad B. Omer
Pages 3761-3770

Research article  Full text access
Jabbing together? The complementarity between social capital, formal public health rules, and COVID-19 vaccine rates in the United States
Byron Carson, Justin Isaacs, Tony Carilli
Pages 3781-3787

Research article  Open access
Experimental pre-tests of public health communications on the COVID-19 vaccine: A null finding for medical endorsement, risk and altruism
Deirdre A. Robertson, Kieran S. Mohr, Martina Barjaková, Peter D. Lunn
Pages 3788-3796

Value in Health
June 2022  Volume 25  Issue 6  p869-1062
https://www.valueinhealthjournal.com/current
[Reviewed earlier]
Better pandemic preparedness does correlate with lower COVID-19 mortality [version 1; peer review: awaiting peer review]

Scott F Dowell, Haidong Wang, David Blazes

Abstract
Paradoxically, many countries with strong pandemic preparedness have reported high coronavirus disease 2019 (COVID-19) mortality. After adjusting for country under-reporting by using total excess mortality estimates, and age distributions by using indirect standardization, we find the resulting comparative mortality ratios are predicted by pandemic preparedness. Countries with higher scores on the Global Health Security Index had significantly lower COVID-19 mortality (r(192) = -0.32, p<0.001). These findings can help inform and prioritize future pandemic preparedness work.

Digitalization impacts the COVID-19 pandemic and the stringency of government measures
Helen Heinrichs, Florian Mueller, Lucia Rohfleisch, Volkmar Schulz, Steven R. Talbot, Fabian Kiessling

A systematic review of dengue outbreak prediction models: current scenario and future directions
Xing Yu Leung, Rakibul M Islam, Mohammadmehdi Adhami, Dragan Ilic, Lara McDonald, Shanika Palawaththa, Basia Diug, Saif U Munshi, Md Nazmul Karim

Racial Disparities in Hesitancy and Utilization of Monoclonal Antibody Infusion Treatment of COVID-19
Drivers of COVID-19 policy stringency in 175 countries and territories: COVID-19 cases and deaths, gross domestic products per capita, and health expenditures
medRxiv 2022.07.05.22277269; doi: https://doi.org/10.1101/2022.07.05.22277269

Persistent immunity after mild SARS CoV-2 infection - The CoNAN-LONG TERM STUDY
Clara Schnizer, Nico Andreas, Wolfgang Vivas, Thomas Kamradt, Michael Baier, Michael Kiehntopf, Stefan Glöckner, André Scherag, Bettina Löfler, Steffi Kolanos, Joel Guerra, Mathias W. Pletz, Sebastian Weis, the CoNAN study group
medRxiv 2022.07.05.22277237; doi: https://doi.org/10.1101/2022.07.05.22277237

Parental acceptance of and preferences for administration of routine varicella vaccination in the UK: a study to inform policy
Susan M. Sherman, Nicola Lingley-Heath, Jasmine Lai, Julius Sim, Helen Bedford
medRxiv 2022.07.05.22277268; doi: https://doi.org/10.1101/2022.07.05.22277268

Quantifying the impact of vaccines and booster doses on COVID-19 in the U.S.
Hemaho B. Taboe, Michael Asare-Baah, Enahoro A. Iboi, Calistus N. Ngonghala
medRxiv 2022.07.06.22277303; doi: https://doi.org/10.1101/2022.07.06.22277303

Waning of SARS-CoV-2 vaccine-induced immunity: A systematic review and secondary data analysis
Francesco Menegale, Mattia Manica, Agnese Zardini, Giorgio Guzzetta, Valentina Marziano, Valeria d’Andrea, Filippo Trentini, Marco Ajelli, Piero Poletti, Stefano Merler
medRxiv 2022.07.04.22277225; doi: https://doi.org/10.1101/2022.07.04.22277225

Asymptomatic Monkeypox virus infections among male sexual health clinic attendees in Belgium
Irith De Baetselier, Christophe Van Dijck, Chris Kenyon, Jasmine Coppens, Dorien Van den Bossche, Hilde Smet, Laurens Liesenborughs, Fien Vanroye, Tessa de Block, Antonio Rezende, Eric Florence, Koen Vercauteren, Marjan Van Esbroeck, the Monkeypox study group
medRxiv 2022.07.04.22277226; doi: https://doi.org/10.1101/2022.07.04.22277226

Using machine learning probabilities to identify effects of COVID-19
Vijendra Ramlall, Benjamin May, Nicholas P Tatonetti
medRxiv 2022.07.02.22277179; doi: https://doi.org/10.1101/2022.07.02.22277179

Environmental surveillance of poliovirus in four districts within two regions of Ghana
Ernest Obese-Djomoah, Evangeline Obodai, Emmanuel Gberbi, Ewurabena Duker, Keren Attiku, Miriam Eshun, Bismarck Boahene, Samuel Victor Nuvor, John Kofi Odoom
medRxiv 2022.07.02.22277180; doi: https://doi.org/10.1101/2022.07.02.22277180

Impact of age-structure and vaccine prioritization on COVID-19 in West Africa
Hemaho B. Taboe, Michael Asare-Baah, Afsana Yesmin, Calistus N. Ngonghala
medRxiv 2022.07.03.22277195; doi: https://doi.org/10.1101/2022.07.03.22277195
Understanding the impact of disease and vaccine mechanisms on the importance of optimal vaccine allocation*

Isobel R. Abell, James M. McCaw, Christopher M. Baker

medRxiv 2022.06.30.22277126; doi: https://doi.org/10.1101/2022.06.30.22277126

OSF Pre-prints
https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences
[Accessed 09 Jul 2022]
No new digest content identified.

Wellcome Open Research [to 09 Jul 2022]
https://wellcomeopenresearch.org/browse/articles
[Accessed 09 Jul 2022]
Selected Research
No new digest content identified.

Think Tanks

Brookings [to 09 Jul 2022]
http://www.brookings.edu/
Accessed 09 Jul 2022
Latest Research
[No new digest content identified]

Center for Global Development [to 25 Jun 2022]
https://www.cgdev.org/
All Research [Selected]
[No new digest content identified]

Chatham House [to 09 Jul 2022]
https://www.chathamhouse.org/
Accessed 09 Jul 2022
[No new digest content identified]

CSIS [to 09 Jul 2022]
https://www.csis.org/
Selected Reports
Report
Genomes: The Era of Purposeful Manipulation Begins
The purposeful manipulation of genomes holds great economic promise and has broad strategic implications. If the United States wants to ensure leadership in this sector, the DOD needs to make structural reforms in its approach to emerging technologies.

**Kaiser Family Foundation**
https://www.kff.org/search/?post_type=press-release
*Accessed 09 Jul 2022*
[No new digest content identified]

**ODI [Overseas Development Institute]**  [to 09 Jul 2022]
*Publications*
*Accessed 09 Jul 2022*
[No new digest content identified]

**Rand**  [to 25 Jun 2022]
https://www.rand.org/pubs.html
[No new digest content identified]

**Urban Institute**  [to 09 Jul 2022]
https://www.urban.org/publications
*New Research Publications*
[No new digest content identified]

**World Economic Forum**  [to 09 Jul 2022]
https://agenda.weforum.org/news/
*No new digest content identified.*

* * * * *
* * * *

---

**Vaccines and Global Health: The Week in Review** is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global Foundation, which is solely responsible for its content.

Copyright GE2P2 Global Foundation 2022. Some Rights Reserved.

This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.
Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation The Rockefeller foundation, Boston University, or 3-D Commission logos is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.

CVEP is a program of the [GE2P2 Global Foundation](#) whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the [Bill & Melinda Gates Foundation](#); the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * * *
* * * * *

* * * * *

* * * *